

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C12N 15/12, 15/70, 15/85, 15/81, 1/19, 1/21, 5/10, 5/20, 7/01, C12Q 1/68, C07K 14/705, 16/28, G01N 33/53, A61K 38/17</p>	<p>A2</p>	<p>(11) International Publication Number: WO 98/39440</p> <p>(43) International Publication Date: 11 September 1998 (11.09.98)</p>
<p>(21) International Application Number: PCT/US98/04267</p> <p>(22) International Filing Date: 4 March 1998 (04.03.98)</p> <p>(30) Priority Data: 08/811,519 4 March 1997 (04.03.97) US</p> <p>(71) Applicant: NEW YORK UNIVERSITY [US/US]; 550 First Avenue, New York, NY 10016 (US).</p> <p>(72) Inventors: PETRENKO, Alexandre, G.; 1802 Hunter Place, Fair Lawn, NJ 07410 (US). KRASNOPEROV, Valery, G.; Apartment #2, 1151 71st Street, Brooklyn, NY 11228 (US).</p> <p>(74) Agents: JACKSON, David, A. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).</p>		<p>(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: CALCIUM INDEPENDENT RECEPTOR OF α-LATROTOXIN, CHARACTERIZATION AND USES THEREOF</p> <p>(57) Abstract</p> <p>A novel receptor of α-latrotoxin (α-LTx) which binds α-LTx independently of calcium (Ca^{2+}) presence and is thus a mediator of the calcium-independent stimulation of neurotransmitter release by α-latrotoxin has been isolated, purified and characterized. Designated CIRL (calcium-independent receptor of α-latrotoxin), it and its endogenous ligands can be used to modulate and regulate spontaneous calcium-independent neurotransmitter release and produce α-latrotoxin-like effects on the nerve terminal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CALCIUM INDEPENDENT RECEPTOR OF α -LATROTOXIN, CHARACTERIZATION AND USES THEREOF

This work was supported by Public Health Service grants R01NS35098 and
5 R01NS34937 from the National Institutes of Health. The government may have
certain rights herein.

TECHNICAL FIELD OF THE INVENTION

10 The present invention relates generally to receptors implicated in neurotransmitter
release, and particularly to a novel G-protein-coupled receptor which binds α -
latrotoxin (α -LTx) independently of calcium (Ca^{2+}) presence and is thus a regulator
of neurotransmitter release which mediates the calcium-independent stimulation of
neurotransmitter release by α -latrotoxin.

15

BACKGROUND OF THE INVENTION

α -Latrotoxin, a vertebrate neurotoxin of Black Widow Spider venom, is a strong
stimulator of spontaneous neurotransmitter release from the nerve terminal (Clark *et*
20 *al.*, 1970, *Nature*, 225 703-705). In physiological solutions, α -latrotoxin-evoked
neurotransmitter release occurs by synaptic vesicle exocytosis and is accompanied
by presynaptic membrane polarization and the influx of calcium ions through the
channels induced by the toxin and through presynaptic calcium channels. However,
an unusual characteristic of α -latrotoxin's stimulatory action is that it does not
25 require extracellular Ca^{2+} , provided Mg^{2+} is present in the extracellular solution and
can occur even without a noticeable increase in intracellular Ca^{2+} concentration.
Stimulation of neurotransmitter release by α -latrotoxin requires binding to its high-
affinity membrane receptors. An immunofluorescence study of the neuromuscular
junction indicates that the α -latrotoxin receptors may not be restricted to the areas of
30 synaptic contacts. Two types of receptors, differing in their calcium requirement of
 α -latrotoxin-binding have been described. The calcium-dependent receptor has been
identified as neurexin I α , a member of a large family of multiply spliced neuron-

specific proteins, the neurexins. In contrast, brain glycoprotein of the Mr 120,000 which does not belong to the neurexin family recently has been purified and proposed as a calcium-independent receptor for, and a likely mediator of, the calcium-independent stimulation of neurosecretion by α -latrotoxin (Krasnoperov *et al.*, (1996), *Biochem. Biophys. Res. Commun.*, **227**:868-875 and Davletov *et al.*, (1996) *J. Biol Chem.* **271**, 23239-23245).

α -Latrotoxin receptors have been identified biochemically, using an iodinated radioactive derivative of the toxin by Tzeng and Siekevitz, *J. Neurochem.* (1979) **33**, 263-274; Meldolesi, *J. Neurochem.* (1982) **38**, 1559-1569; Scheer and Meldolesi, *EMBO J.* (1985) **4**, 323-327. These receptors were of low abundance (about 300 fmol/mg of membrane protein), and their affinity to α -latrotoxin was high (Kd in the range of 10^{-9} - 10^{-10} M). Previously, the purification of a high-affinity α -latrotoxin-binding protein was identified as neurexin I α , a member of a large family of multiply spliced neuron-specific proteins, the neurexins was reported in Petrenko, *FEBS Lett.* (1993) **325**, 81-85; Petrenko *et al.*, (1990) *EMBO J.* **9**, 2023-2027; and Ushkaryov *et al.*, *Science* (1992) **257**, 50-56. The structural features and developmental profile of neurexins suggest that they perform a function in cell adhesion or recognition important in axonogenesis, see, Ushkaryov *et al.*, *Science* (1992) **257**, 50-56; and Puschel and Betz, *J. Neurosci.* (1995) **15**, 2849-2856. A hypothesis has been formulated that these highly polymorphic cell surface membrane proteins may define the specificity of synaptic connections in the brain Ushkaryov *et al.*, *Science* (1992) **257**, 50-56.

α -Latrotoxin-binding properties of purified and recombinant neurexin-I α are very similar to the binding properties of the membrane-bound α -latrotoxin receptors with one significant exception: neurexin I α binds α -latrotoxin only in the presence of calcium, whereas the brain membranes bind the toxin even in the presence of EDTA. Therefore, neurexin I α may be important in calcium-dependent effects of α -latrotoxin, such as degeneration of nerve terminals, but not in the stimulation of

neurosecretion in calcium-independent environment. Since purified α -latrotoxin can form cation channels in artificial lipid bilayers, neurexin I α may facilitate its insertion into the cellular membrane by binding with α -latrotoxin, resulting in calcium fluxes through the formed cation channels. However, in the absence of calcium, this mechanism would not explain robust stimulation of spontaneous neurotransmitter release by this toxin.

In view of the above, a need therefore exists to elucidate the calcium-independent activation of α -latrotoxin, and to thereby further understand its activity, and possibly devise strategies for intervention that may benefit neuronal activity. It is accordingly toward the fulfillment of these needs that the present invention is directed.

SUMMARY OF THE INVENTION

In one aspect, the present invention concerns the identification of a second α -latrotoxin receptor which binds α -latrotoxin both in the presence or absence of calcium and is pharmacologically and structurally distinct from neurexin I α , an earlier described receptor of α -latrotoxin. This receptor, designated CIRL (calcium-independent receptor of α -latrotoxin) belongs to the secretin receptor subfamily of G-protein coupled receptors, and, together with α -latrotoxin, interacts with syntaxin, a component of the neuronal exocytotic machinery. CIRL, as a neuronal signaling receptor, is thus critically important for the calcium-independent stimulation of neurotransmitter release by α -latrotoxin.

A further aspect of the present invention involves the isolation, purification and characterization of the calcium-independent receptor of α -latrotoxin (CIRL).

In its broadest aspect, the present invention extends to a novel neuronal receptor which is a regulator of neurotransmitter release, and thus mediates α -latrotoxin (α -LTx) toxicity both in the presence or absence of calcium.

In a specific example, the calcium-independent receptor of α -latrotoxin (CIRL) has been identified as a G-protein-coupled receptor which contains a subunit of an apparent Mr 120,000, as determined by SDS-PAGE analysis.

5

In a still further aspect, the present invention extends to methods of utilizing CIRL. This receptor can be expressed and used to screen libraries of agents, or mixtures of natural origin (*e.g.*, brain homogenates, detergent extracts, cell conditioned media or extracts, *etc.*) for ligands thereof which can then be utilized in various therapeutic

10 methods.

Still further, since this receptor is enriched in the striatum of the mammalian brain, antibodies or nucleic acid probes thereto can be prepared which can then be utilized in diagnostic methods for screening for the presence of various neurological diseases characterized by the changes in receptor expression, or mutations thereto, or the presence of excess receptors. These diseases include, but are not limited to, neurological diseases such as schizophrenia, Alzheimer's disease, epilepsy, stress disorder, Huntington's disease, Parkinson's disease, as well as peripheral neuromuscular diseases such as myasthenia gravis.

20

In a particular embodiment, the present invention relates to all members of the herein disclosed family of calcium-independent receptors of α -latrotoxin, and to genetically engineered cells which express such receptors.

25 The present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes a calcium-independent receptor of α -latrotoxin (CIRL); preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the calcium-independent receptor of α -latrotoxin (CIRL), having a nucleotide sequence or is complementary to a DNA
30 sequence shown in FIGURE 2B (SEQ ID NO:2). In a still further embodiment, the

gene constructs of this invention can be utilized in gene therapy in individuals wherein the lack of, or changes in, or modifications to, this receptor causes deficits in neurotransmission.

5 The human and murine DNA sequences of the calcium-independent receptor of α -latrotoxin (CIRL) of the present invention or portions thereof, may be prepared as probes to screen for ligands, complementary sequences and genomic clones in the same or alternate species. The present invention extends to probes so prepared that may be provided for screening cDNA and genomic libraries for the calcium-
10 independent receptor of α -latrotoxin (CIRL). For example, the probes may be prepared with a variety of known vectors, such as the phage λ vector. The present invention also includes the preparation of plasmids including such vectors, and the use of the DNA sequences to construct vectors expressing antisense RNA or ribozymes which would attack the mRNAs of any or all of the DNA sequences set
15 forth in FIGURE 2B (SEQ ID NO:2, respectively). Correspondingly, the preparation of antisense RNA and ribozymes are included herein.

The present invention also includes calcium-independent receptor of α -latrotoxin (CIRL) proteins having the activities noted herein, and that display the amino acid
20 sequences set forth and described above and selected from SEQ ID NO:1, and subunits thereof.

In a further embodiment of the invention, the full DNA sequence of the recombinant DNA molecule or cloned gene so determined may be operatively linked to an
25 expression control sequence which may be introduced into an appropriate host. The invention accordingly extends to host cells transformed with the cloned gene or recombinant DNA molecule comprising a DNA sequence encoding the present calcium-independent receptor of α -latrotoxin (CIRL)(s), and more particularly, the complete DNA sequence determined from the sequences set forth above and in SEQ
30 ID NO:2.

According to other preferred features of certain preferred embodiments of the present invention, a recombinant expression system is provided to produce biologically active animal or human calcium-independent α -latrotoxin receptor (CIRL). The transgenic animals can also include a "knock-out" animal as a model
5 of the various diseases.

The concept of the calcium-independent receptor of α -latrotoxin (CIRL) contemplates that specific receptors exist for correspondingly specific ligands, such as α -latrotoxin and the like, as described earlier. Accordingly, the exact structure
10 of each calcium-independent receptor of α -latrotoxin (CIRL) will understandably vary so as to achieve this ligand and activity specificity. It is this specificity and the direct involvement of the calcium-independent receptor of α -latrotoxin (CIRL) in the chain of events leading to release of neurotransmitters, that offers the promise of a broad spectrum of diagnostic and therapeutic utilities.

15 The present invention naturally contemplates several means for preparation of the calcium-independent receptor of α -latrotoxin (CIRL), including as illustrated herein known recombinant techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The isolation of the CDNA and amino
20 acid sequences disclosed herein facilitates the reproduction of the calcium-independent receptor of α -latrotoxin (CIRL) by such recombinant techniques, and accordingly, the invention extends to expression vectors prepared from the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.

25 The invention includes an assay system for screening of potential drugs effective to modulate activities of target mammalian cells by interrupting or potentiating the calcium-independent receptor of α -latrotoxin (CIRL). In one instance, the test drug could be administered to a cellular sample with the ligand that activates the calcium-
30 independent receptor of α -latrotoxin (CIRL), or an extract containing the activated

calcium-independent receptor of α -latrotoxin (CIRL), to determine its effect upon the binding activity of the calcium-independent receptor of α -latrotoxin (CIRL) to any chemical sample (including DNA), or to the test drug, by comparison with a control.

5

The assay system could more importantly be adapted to identify drugs or other entities that are capable of binding to the calcium-independent receptor of α -latrotoxin (CIRL) and/or calcium-independent receptor of α -latrotoxin (CIRL) factors or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or
10 potentiating calcium-independent receptor of α -latrotoxin (CIRL) activity. Such assay would be useful in the development of drugs that would be specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity. For example, such drugs might be used to modulate and/or reverse the degeneration of nerve terminals, to modulate synaptic transmission, or to treat other
15 pathologies, as for example, in making calcium-independent receptor of α -latrotoxin (CIRL) more resistant to α -latrotoxin.

In yet a further embodiment, the invention contemplates antagonists of the activity of a calcium-independent receptor of α -latrotoxin (CIRL). In particular, an agent or
20 molecule that inhibits calcium-independent receptor of α -latrotoxin (CIRL) is an embodiment of the present invention. In a specific embodiment, the antagonist can be a peptide having the sequence of a portion of an calcium-independent receptor of α -latrotoxin (CIRL) domain.

25 One of the characteristics of the present calcium-independent receptor of α -latrotoxin (CIRL) is that it is a G-coupled-protein having a subunit of apparent Mr 120,000 by SDS-PAGE Analysis.

The diagnostic utility of the present invention extends to the use of the present
30 calcium-independent receptor of α -latrotoxin (CIRL) in assays to screen for calcium-

independent receptor of α -latrotoxin (CIRL).

The present invention likewise extends to the development of antibodies against the calcium-independent receptor of α -latrotoxin (CIRL)(s), including naturally raised
5 and recombinantly prepared antibodies. For example, the antibodies could be used to screen expression libraries to obtain the gene or genes that encode the calcium-independent receptor of α -latrotoxin (CIRL)(s). Such antibodies could include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other
10 functionalities suiting them for additional diagnostic use conjunctive with their capability of modulating calcium-independent receptor of α -latrotoxin (CIRL) activity.

In particular, antibodies against specifically phosphorylated factors can be selected
15 and are included within the scope of the present invention for their particular ability in following activated protein. Thus, activity of the calcium-independent receptor of α -latrotoxin (CIRL) or of the specific polypeptides believed to be causally connected thereto may therefore be followed directly by the assay techniques discussed later on, through the use of an appropriately labeled quantity of the calcium-independent
20 receptor of α -latrotoxin (CIRL) or antibodies or analogs thereof.

Thus, the calcium-independent receptor of α -latrotoxin (CIRL), their analogs and/or analogs, and any antagonists or antibodies that may be raised thereto, are capable of use in connection with various diagnostic techniques, including immunoassays, such
25 as a radioimmunoassay, using for example, an antibody to the calcium-independent receptor of α -latrotoxin (CIRL) that has been labeled by either radioactive addition, or radioiodination.

In an immunoassay, a control quantity of the antagonists or antibodies thereto, or
30 the like may be prepared and labeled with an enzyme, a specific binding partner

and/or a radioactive element, and may then be introduced into a cellular sample. After the labeled material or its binding partner(s) has had an opportunity to react with sites within the sample, the resulting mass may be examined by known techniques, which may vary with the nature of the label attached.

5

In the instance where a radioactive label, such as the isotopes ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and ^{186}Re are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

10

The present invention includes an assay system which may be prepared in the form of a test kit for the quantitative analysis of the extent of the presence of the calcium-independent receptor of α -latrotoxin (CIRL), or to identify drugs or other agents that may mimic or block its activity. The system or test kit may comprise a labeled component prepared by one of the radioactive and/or enzymatic techniques discussed herein, coupling a label to the calcium-independent receptor of α -latrotoxin (CIRL), their agonists and/or antagonists, and one or more additional immunochemical reagents, at least one of which is a free or immobilized ligand, capable either of binding with the labeled component, its binding partner, one of the components to be determined or their binding partner(s).

15

20

In a further embodiment, the present invention relates to certain therapeutic methods which would be based upon the activity of the calcium-independent receptor of α -latrotoxin (CIRL)(s), genetically engineered cells which express or secrete CIRL, its (or their) subunits, or active fragments thereof, or upon agents or other drugs determined to possess the same activity. A first therapeutic method is associated with the prevention of the manifestations of conditions causally related to or following from the binding activity of the calcium-independent receptor of α -

25

30

latrotoxin (CIRL) or its subunits, and comprises administering an agent capable of modulating the production and/or activity of the calcium-independent receptor of α -latrotoxin (CIRL) or subunits thereof, either individually or in mixture with each other in an amount effective to prevent the development of those conditions in the host. For example, drugs or other binding partners to the calcium-independent receptor of α -latrotoxin (CIRL) or proteins may be administered to inhibit or potentiate calcium-independent receptor of α -latrotoxin (CIRL) activity, as in the potentiation of calcium-independent receptor of α -latrotoxin (CIRL) in therapy. Also, the blockade of the action of specific phosphatases in the dephosphorylation of activated (phosphorylated) calcium-independent receptor of α -latrotoxin (CIRL) or proteins presents a method for potentiating the activity of the calcium-independent receptor of α -latrotoxin (CIRL) or protein that would concomitantly potentiate therapies based on calcium-independent receptor of α -latrotoxin (CIRL)/protein activation.

More specifically, the therapeutic method generally referred to herein could include the method for the treatment of various pathologies or other cellular dysfunctions and derangements by the administration of pharmaceutical compositions that may comprise effective inhibitors or enhancers of activation of the calcium-independent receptor of α -latrotoxin (CIRL) or its subunits, or other equally effective drugs developed for instance by a drug screening assay prepared and used in accordance with a further aspect of the present invention. For example, drugs or other binding partners to the calcium-independent receptor of α -latrotoxin (CIRL) or proteins, as represented by SEQ ID NO:1, may be administered to inhibit or potentiate calcium-independent receptor of α -latrotoxin (CIRL) activity as in the potentiation of calcium-independent receptor of α -latrotoxin (CIRL) in therapy.

In particular, the proteins of calcium-independent receptor of α -latrotoxin (CIRL) whose sequences are presented in SEQ ID NO:1 herein, their antibodies, agonists, antagonists, active fragments thereof, or expressing cells thereof, could be prepared

in pharmaceutical formulations for administration in instances wherein calcium-independent receptor of α -latrotoxin (CIRL) therapy is appropriate, such as to modulate and/or prevent nerve degeneration, or to modulate neurotransmitter release.

5 Accordingly, it is a principal object of the present invention to provide a calcium-independent receptor of α -latrotoxin (CIRL) and its subunits in purified form that exhibits certain characteristics and activities associated with calcium-independent receptor of α -latrotoxin (CIRL) activity.

10 It is a further object of the present invention to provide antibodies to the calcium-independent receptor of α -latrotoxin (CIRL) and its subunits, and methods for their preparation, including recombinant means.

It is a further object of the present invention to provide a method for detecting the
15 presence of the calcium-independent receptor of α -latrotoxin (CIRL) and its subunits in mammals in which invasive, spontaneous, or idiopathic pathological states are suspected to be present.

It is a further object of the present invention to provide a method and associated
20 assay system for screening substances such as drugs, agents and the like, potentially effective in either mimicking the activity or combating the adverse effects of the calcium-independent receptor of α -latrotoxin (CIRL) and/or its subunits in mammals.

25 It is a still further object of the present invention to provide a method for the treatment of mammals to control the amount or activity of the calcium-independent receptor of α -latrotoxin (CIRL) or subunits thereof, so as to alter the adverse consequences of such presence or activity, or where beneficial, to enhance such activity.

30

It is a still further object of the present invention to provide a method for the treatment of mammals to control the amount or activity of the calcium-independent receptor of α -latrotoxin (CIRL) or its subunits, so as to treat or avert the adverse consequences of invasive, spontaneous or idiopathic pathological states.

5

It is a still further object of the present invention to provide pharmaceutical compositions for use in therapeutic methods which comprise or are based upon the calcium-independent receptor of α -latrotoxin (CIRL), its subunits, their binding partner(s), or upon agents or drugs that control the production, or that mimic or

10 antagonize the activities of the calcium-independent receptor of α -latrotoxin.

Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description which proceeds with reference to the following

15 illustrative drawings.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

FIGURE 1 is a graph showing two types of α -latrotoxin receptors in brain

20 membranes as detected by lectin inhibition. The specific binding of iodinated α -latrotoxin to rat brain membranes preincubated with different concentrations of Concanavalin A was analyzed in the presence of Ca^{2+} (2 nM) or its absence (3 mM EDTA). Squares and a solid line denotes the binding activity in the absence of calcium. Open circles and a dotted line describes the difference between the binding

25 activity measured in the presence of calcium and in the absence of calcium.

FIGURE 2A is the predicted amino acid sequence of CIRL precursor protein.

FIGURE 2B is the predicted sequence of DNA encoding CIRL precursor protein.

30

FIGURE 3A is a graph showing the expression of functionally active CIRL in COS cells. COS cells were transfected with CIRL expression construct in pcDNA 3.1 vector (Invitrogen) by calcium phosphate precipitate method. In two days, the cells were harvested, lysed and crude cell membranes were analyzed for α -latrotoxin binding activity. Approximately 20 % of cell material harvested from one 100 mm Petri dish was used for each measurement in the binding assay. In parallel, α -latrotoxin binding activity of rat brain membranes (220 μ g protein) was measured under identical conditions. The value of specific binding was calculated by subtraction of the non-specific binding obtained in the presence of 0.1 μ M α -latrotoxin from the total binding for each α -latrotoxin concentration. The results of binding assays are presented in a Scatchard plot.

FIGURE 3B is a gel showing the binding with anti-Mr 120,000 subunit antibody. COS cells were transfected with an expression plasmid encoding N-terminal 1-850 residues. In two days, the cell media were collected and 1 ml of media was incubated with 10 ml of a latrotoxin-Sepharose for 1 hour at room temperature on a shaker. The mixture was pelleted, the matrix was eluted with SDS sample buffer (pellet) and together with 30 ml of the media (supernatant), analyzed by electrophoresis and Western blotting with anti-Mr 120,000 subunit antibody.

20

FIGURES 4A-B are diagrams respecting the domain structure of CIRL. FIGURE 4A shows homology with some secretin receptor family of protein.

FIGURE 5 shows the distribution of CIRL in different brain regions. Rat brains were dissected to separate cortex, striatum, thalamus, hippocampus and cerebellum. The tissues were homogenized in 150 mM NaCl, 50mM TrisHCl and 2mM EDTA buffer, pH 7.9 and the crude membrane fractions were obtained by centrifugation. A. The specific binding of 0.5 nM 125 I- α -latrotoxin to the membranes was analyzed in the buffer containing either 2mM Ca^{2+} or 2 mM EDTA in triplicates. A 100-fold excess of cold α -latrotoxin was added to the control for non-specific binding.

30

Calcium-independent binding activity was calculated as a difference between α -latrotoxin binding measured in the presence of Ca^{2+} and in EDTA-containing buffer.

B. The same membrane samples were blotted with the anti-CIRL antibody. When the films of ECL-developed blots with difference exposures were quantitated, all of
5 them showed a larger concentration of CIRL in the striatum than in the cortex by about 40%.

FIGURE 6 is a gel showing that CIRL is a glycoprotein. 0.2 mg of affinity purified CIRL were incubated with Neuraminidase, PNGase F and o-Glycanase for 2 hours
10 at 37°C. In control reactions, no enzyme was added. Reaction mixes were resolved on a 10 % SDS gel and blotted onto nitrocellulose. The blot was immunostained with anti-CIRL antibody.

FIGURES 7A and 7B illustrate the interaction of CIRL with syntaxin. FIGURE 7A
15 shows the co-purification of syntaxin and synaptotagmin with CIRL on an α -latrotoxin affinity column. The total rat brain membranes in the amount of 35 mg or affinity purified CIRL in the amount of 0.15 mg were loaded on a 9 % SDS gel and immunostained with the antibodies against syntaxin (anti-Syx), synaptotagmin (anti-Syt) and synaptophysin (anti-Syph). FIGURE 7B shows the
20 immunoprecipitation of α -latrotoxin-binding activity. The complex of ^{125}I - α -latrotoxin was preformed in the extracts of total brain membranes and immunoprecipitated as described below in the Examples section. Lanes 1 - the precipitated binding activity by the corresponding antibody. Lanes 2 - no brain membrane extract added. Lane 3 - pre-immune serum or normal mouse IgGs added
25 to brain extracts. Lane 4 - the same as in 3 without brain extracts.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention there may be employed conventional
30 molecular biology, microbiology, and recombinant DNA techniques within the skill

- of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al, "Molecular Cloning: A Laboratory Manual" (1989); "Current Protocols in Molecular Biology" Volumes I-III [Ausubel, R. M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes I-III [J. E. Celis, ed. (1994)];
- 5 "Current Protocols in Immunology" Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A
- 10 Practical Guide To Molecular Cloning" (1984).

Therefore, if appearing herein, the following terms shall have the definitions set out below.

- 15 The terms "calcium-independent receptor of α -latrotoxin," "CIRL", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIGURE 2A (SEQ ID NO:1), and active subunits
- 20 thereof, and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex
- 25 or its named subunits. Also, the terms "calcium-independent receptor of α -latrotoxin," and "CIRL" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs, allelic variations and active subunits thereof.
- 30 The amino acid residues described herein are preferred to be in the "L" isomeric

form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH_2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, **243**:3552-59 (1969), abbreviations for amino acid residues are shown in the following Table of Correspondence:

TABLE OF CORRESPONDENCE

<u>SYMBOL</u>		<u>AMINO ACID</u>	
	<u>1-Letter</u>	<u>3-Letter</u>	
10	Y	Tyr	tyrosine
	G	Gly	glycine
	F	Phe	phenylalanine
	M	Met	methionine
15	A	Ala	alanine
	S	Ser	serine
	I	Ile	isoleucine
	L	Leu	leucine
	T	Thr	threonine
20	V	Val	valine
	P	Pro	proline
	K	Lys	lysine
	H	His	histidine
	Q	Gln	glutamine
25	E	Glu	glutamic acid
	W	Trp	tryptophan
	R	Arg	arginine
	D	Asp	aspartic acid
	N	Asn	asparagine
30	C	Cys	cysteine

It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. The above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.

A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; i.e., capable of replication under its own control.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA).

An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

10

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

15 A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements
20 necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic
25 promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is
30 "under the control" of transcriptional and translational control sequences in a cell

when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

A "signal sequence" can be included before the coding sequence. This sequence
5 encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

10

The term "oligonucleotide," as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

15

The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a
20 nucleic acid strand, is induced, *i.e.*, in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including
25 temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

30 The primers herein are selected to be "substantially" complementary to different

strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

10

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

15 A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to
20 eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived
25 from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

It should be appreciated that also within the scope of the present invention are DNA sequences encoding the calcium-independent receptor of α -latrotoxin (CIRL) which
30 code for a calcium-independent receptor of α -latrotoxin (CIRL) having the same

amino acid sequence as SEQ ID NO:1, but which are degenerate to SEQ ID NO:1. By "degenerate to" is meant that a different three-letter codon is used to specify a particular amino acid. It is well known in the art that the following codons can be used interchangeably to code for each specific amino acid:

5	Phenylalanine (Phe or F)	UUU or UUC
	Leucine (Leu or L)	UUA or UUG or CUU or CUC or CUA or CUG
	Isoleucine (Ile or I)	AUU or AUC or AUA
	Methionine (Met or M)	AUG
10	Valine (Val or V)	GUU or GUC or GUA or GUG
	Serine (Ser or S)	UCU or UCC or UCA or UCG or AGU or AGC
	Proline (Pro or P)	CCU or CCC or CCA or CCG
	Threonine (Thr or T)	ACU or ACC or ACA or ACG
	Alanine (Ala or A)	GCU or GCG or GCA or GCG
15	Tyrosine (Tyr or Y)	UAU or UAC
	Histidine (His or H)	CAU or CAC
	Glutamine (Gln or Q)	CAA or CAG
	Asparagine (Asn or N)	AAU or AAC
	Lysine (Lys or K)	AAA or AAG
20	Aspartic Acid (Asp or D)	GAU or GAC
	Glutamic Acid (Glu or E)	GAA or GAG
	Cysteine (Cys or C)	UGU or UGC
	Arginine (Arg or R)	CGU or CGC or CGA or CGG or AGA or AGG
	Glycine (Gly or G)	GGU or GGC or GGA or GGG
25	Tryptophan (Trp or W)	UGG
	Termination codon	UAA (ochre) or UAG (amber) or UGA (opal)

It should be understood that the codons specified above are for RNA sequences.

The corresponding codons for DNA have a T substituted for U.

Mutations can be made in SEQ ID NO:2 such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (*i.e.*, by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (*i.e.*, by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative change is more likely to alter the structure, activity or function of the resulting protein. The present invention should be considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein.

15

The following is one example of various groupings of amino acids:

Amino acids with nonpolar R groups

20 Alanine

Valine

Leucine

Isoleucine

Proline

25 Phenylalanine

Tryptophan

Methionine

Amino acids with uncharged polar R groups

Glycine

Serine

Threonine

5 Cysteine

Tyrosine

Asparagine

Glutamine

10 Amino acids with charged polar R groups (negatively charged at pH 6.0)

Aspartic acid

Glutamic acid

15 Basic amino acids (positively charged at pH 6.0)

Lysine

Arginine

Histidine (at pH 6.0)

20

Another grouping may be those amino acids with phenyl groups:

Phenylalanine

Tryptophan

25 Tyrosine

Another grouping may be according to molecular weight (*i.e.*, size of R groups):

Glycine 75

30 Alanine 89

	Serine	105
	Proline	115
	Valine	117
	Threonine	119
5	Cysteine	121
	Leucine	131
	Isoleucine	131
	Asparagine	132
	Aspartic acid	133
10	Glutamine	146
	Lysine	146
	Glutamic acid	147
	Methionine	149
	Histidine (at pH 6.0)	155
15	Phenylalanine	165
	Arginine	174
	Tyrosine	181
	Tryptophan	204

20 Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free NH₂ can be maintained.

25

Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site for disulfide bridges with another Cys. A His may be introduced as a particularly "catalytic" site (i.e., His can act as an acid or base and is the most

30 common amino acid in biochemical catalysis). Pro may be introduced because of its

particularly planar structure, which induces β -turns in the protein's structure.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger
5 molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (*e.g.*, a cDNA where the genomic coding sequence contains introns,
10 or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

An "antibody" is any immunoglobulin, including antibodies and fragments thereof,
15 that binds a specific epitope. The term encompasses polyclonal, monoclonal, bispecific and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567.

An "antibody combining site" is that structural portion of an antibody molecule
20 comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically
25 active portion of an immunoglobulin molecule.

Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab',
30 F(ab')₂ and F(v), which portions are preferred for use in the therapeutic methods

described herein.

Fab and F(ab')₂ portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are produced from F(ab')₂ portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact antibody molecules is preferred herein.

The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; *e.g.*, a bispecific (chimeric) monoclonal antibody.

20

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.

25

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant change in the S phase activity of a target cellular mass, or other feature of pathology such as for example, elevated blood pressure, fever or white cell count

30

as may attend its presence and activity.

A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (*e.g.*, ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and wash. However, one skilled in the art will appreciate that such "standard hybridization conditions" are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like. Also important in the determination of "standard hybridization conditions" is whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20°C below the predicted or determined T_m with washes of higher stringency, if desired.

In its primary aspect, the present invention concerns the identification of a calcium-independent receptor of α -latrotoxin (CIRL).

In a particular embodiment, the present invention relates to all members of the herein disclosed calcium-independent receptor of α -latrotoxin (CIRL).

As stated above, the present invention also relates to a recombinant DNA molecule or cloned gene which encodes a calcium-independent receptor of α -latrotoxin (CIRL) that possesses an apparent molecular weight of about 120,000 kD, as determined by SDS-PAGE analysis, and an amino acid sequence set forth in

5 FIGURE 2A (SEQ ID NO:1). Also, this invention relates to degenerative variants and active fragments of the recombinant DNA molecule.

The possibilities both diagnostic and therapeutic that are raised by the existence of the calcium-independent receptor of α -latrotoxin (CIRL), derive from the fact that

10 this factor appear to be a regulator of neurotransmitter release. As suggested earlier and elaborated further on herein, the present invention contemplates pharmaceutical and/or genetic intervention in the cascade of reactions in which the calcium-independent receptor of α -latrotoxin (CIRL) is implicated.

15 Thus, in instances where it is desired to reduce or inhibit the activity resulting from a particular stimulus or factor, an appropriate inhibitor of the calcium-independent receptor of α -latrotoxin (CIRL) could be introduced to block the interaction of the calcium-independent receptor of α -latrotoxin (CIRL) with such factors.

Correspondingly, instances where insufficient activity is taking place could be

20 remedied by the introduction of additional quantities of the calcium-independent α -latrotoxin receptor or its chemical or pharmaceutical cognates, analogs, fragments and the like.

As discussed earlier, the calcium-independent α -latrotoxin receptor or its binding

25 partners or other ligands or agents exhibiting either mimicry or antagonism to the calcium-independent α -latrotoxin receptor or control over its production, may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration by various means to a patient experiencing an adverse medical condition associated with specific α -latrotoxin toxicity for the treatment

30 thereof. A variety of conventional administrative techniques may be utilized, among

them parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, catheterizations and the like. Other administration techniques, including those which utilize cells that have been genetically modified to express CIRL, and/or suitable delivery systems, such as viral vectors, can be utilized to administer
5 the requisite DNA which will then express the CIRL. Average quantities of the calcium-independent receptor of α -latrotoxin (CIRL) or their subunits may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.

10 Also, antibodies including both polyclonal and monoclonal antibodies, and drugs that modulate the production or activity of the calcium-independent receptor of α -latrotoxin (CIRL) and/or their subunits may possess certain diagnostic applications and may for example, be utilized for the purpose of detecting and/or measuring conditions. For example, the calcium-independent receptor of α -latrotoxin (CIRL)
15 or its subunits may be used to produce both polyclonal and monoclonal antibodies to themselves in a variety of cellular media, by known techniques such as the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells. Likewise, small molecules that mimic or antagonize the activity(ies) of the calcium-independent receptor of α -latrotoxin (CIRL) of the invention may be
20 discovered or synthesized, and may be used in diagnostic and/or therapeutic protocols.

The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal, antibody-producing cell lines can also be created by techniques
25 other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., "Hybridoma Techniques" (1980); Hammerling et al., "Monoclonal Antibodies And T-cell Hybridomas" (1981); Kennett et al., "Monoclonal Antibodies" (1980); see also U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570;
30 4,466,917; 4,472,500; 4,491,632; 4,493,890.

- Panels of monoclonal antibodies produced against calcium-independent receptor of α -latrotoxin (CIRL) peptides can be screened for various properties: i.e., isotope, epitope, affinity, etc. Of particular interest are monoclonal antibodies that neutralize the activity of the calcium-independent receptor of α -latrotoxin (CIRL) or its subunits. Such monoclonals can be readily identified in calcium-independent receptor of α -latrotoxin (CIRL) activity assays. High affinity antibodies are also useful when immunoaffinity purification of native or recombinant calcium-independent receptor of α -latrotoxin (CIRL) is possible.
- 10 Preferably, the anti-calcium-independent receptor of α -latrotoxin (CIRL) antibody used in the diagnostic methods of this invention is an affinity purified polyclonal antibody. More preferably, the antibody is a monoclonal antibody (mAb). In addition, it is preferable for the anti-calcium-independent receptor of α -latrotoxin (CIRL) antibody molecules used herein be in the form of Fab, Fab', F(ab')₂ or F(v)
- 15 portions of whole antibody molecules.

- As suggested earlier, the diagnostic method of the present invention comprises examining a cellular sample or medium by means of an assay including an effective amount of an antagonist to a calcium-independent receptor of α -latrotoxin (CIRL)/protein, such as an anti-calcium-independent receptor of α -latrotoxin (CIRL) antibody, preferably an affinity-purified polyclonal antibody, and more preferably a mAb. In addition, it is preferable for the anti-calcium-independent receptor of α -latrotoxin (CIRL) antibody molecules used herein be in the form of Fab, Fab', F(ab')₂ or F(v) portions or whole antibody molecules. As previously
- 25 discussed, patients capable of benefiting from this method include those suffering from neurological diseases. Methods for inducing anti-calcium-independent receptor of α -latrotoxin (CIRL) antibodies and for determining and optimizing the ability of anti-calcium-independent receptor of α -latrotoxin (CIRL) antibodies to assist in the examination of the target cells are all well-known in the art.

Methods for producing polyclonal anti-polypeptide antibodies are well-known in the art. See U.S. Patent No. 4,493,795 to Nestor et al. A monoclonal antibody, typically containing Fab and/or F(ab')₂ portions of useful antibody molecules, can be prepared using the hybridoma technology described in *Antibodies - A Laboratory*
5 *Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory, New York (1988), which is incorporated herein by reference. Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with a calcium-independent receptor of α -latrotoxin
10 (CIRL)-binding portion thereof, or calcium-independent receptor of α -latrotoxin (CIRL), or an origin-specific DNA-binding portion thereof.

Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 6000. Fused hybrids are selected by their sensitivity to HAT. Hybridomas
15 producing a monoclonal antibody useful in practicing this invention are identified by their ability to immunoreact with the present calcium-independent receptor of α -latrotoxin (CIRL) and their ability to inhibit specified calcium-independent receptor of α -latrotoxin (CIRL) activity in target cells.

20 A monoclonal antibody useful in practicing the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The
25 antibody-containing medium is then collected. The antibody molecules can then be further isolated by well-known techniques.

Media useful for the preparation of these compositions are both well-known in the art and commercially available and include synthetic culture media, inbred mice and
30 the like. An exemplary synthetic medium is Dulbecco's minimal essential medium

(DMEM; Dulbecco et al., *Virol.* 8:396 (1959)) supplemented with 4.5 gm/l glucose, 20 mm glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

- 5 General methodology for producing monoclonal anti-calcium-independent receptor of α -latrotoxin (CIRL) antibodies are also well-known in the art. See Niman et al., *Proc. Natl. Acad. Sci. USA*, 80:4949-4953 (1983). Typically, the present calcium-independent receptor of α -latrotoxin (CIRL) or a peptide analog is used either alone or conjugated to an immunogenic carrier, as the immunogen in the before described
- 10 procedure for producing anti-calcium-independent receptor of α -latrotoxin (CIRL) monoclonal antibodies. The hybridomas are screened for the ability to produce an antibody that immunoreacts with the calcium-independent receptor of α -latrotoxin (CIRL) peptide analog and the present calcium-independent receptor of α -latrotoxin (CIRL).

15

- The present invention further contemplates therapeutic compositions useful in practicing the therapeutic methods of this invention. A subject therapeutic composition includes, in admixture, a pharmaceutically acceptable excipient (carrier) and one or more of a calcium-independent receptor of α -latrotoxin (CIRL),
- 20 polypeptide analog thereof, fragment thereof, or ligand thereto, as described herein as an active ingredient. In a preferred embodiment, the composition comprises an agent capable of modulating the specific binding of the present calcium-independent receptor of α -latrotoxin (CIRL) within a target cell.

- 25 The preparation of therapeutic compositions which contain polypeptides, analogs or active fragments, or ligands as active ingredients is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be
- 30 emulsified. The active therapeutic ingredient is often mixed with excipients which

are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.

A polypeptide, analog, active fragment or ligand can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

The therapeutic polypeptide-, analog-, active fragment- or ligand-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; *i.e.*, carrier, or vehicle.

The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount.

Another feature of this invention is the expression of the DNA sequences disclosed herein. As is well known in the art, DNA sequences may be expressed by

operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host.

- 5 Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.
- 10 A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, *e.g.*, *E. coli* plasmids col El, pCR1, pBR322, pMB9 and their derivatives,
- 15 plasmids such as RP4; phage DNAs, *e.g.*, the numerous derivatives of phage λ , *e.g.*, NM989, and other phage DNA, *e.g.*, M13 and filamentous single-stranded phage DNA; yeast plasmids such as the 2 μ plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids
- 20 that have been modified to employ phage DNA or other expression control sequences; and the like.

- Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these
- 25 vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the *LTR* system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase
- 30 or other glycolytic enzymes, the promoters of acid phosphatase (*e.g.*, Pho5), the

promoters of the yeast α -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

- 5 A wide variety of host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi such as yeasts, and animal cells, especially mammalian cells, such as CHO, RL1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1,
10 BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

- It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither
15 will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in
20 it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

- In selecting an expression control sequence, a variety of factors will normally be
25 considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their
30 fermentation requirements, as well as the toxicity to the host of the product encoded

by the DNA sequences to be expressed, and the ease of purification of the expression products.

Considering these and other factors a person skilled in the art will be able to
5 construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

It is further intended that calcium-independent receptor of α -latrotoxin (CIRL)
10 analogs may be prepared from nucleotide sequences of the protein complex/subunit derived within the scope of the present invention. Analogs, such as fragments, may be produced, for example, by pepsin digestion of calcium-independent receptor of α -latrotoxin (CIRL) material. Other analogs, such as muteins, can be produced by standard site-directed mutagenesis of calcium-independent receptor of α -latrotoxin
15 (CIRL) coding sequences. Analogs exhibiting "calcium-independent receptor of α -latrotoxin (CIRL) activity" such as small molecules, whether functioning as promoters or inhibitors, may be identified by known *in vivo* and/or *in vitro* assays.

As mentioned above, a DNA sequence encoding calcium-independent receptor of α -
20 latrotoxin (CIRL) can be prepared synthetically rather than cloned. The DNA sequence can be designed with the appropriate codons for the calcium-independent receptor of α -latrotoxin (CIRL) amino acid sequence. In general, one will select preferred codons for the intended host if the sequence will be used for expression. The complete sequence is assembled from overlapping oligonucleotides prepared by
25 standard methods and assembled into a complete coding sequence. See, *e.g.*, Edge, *Nature*, **292**:756 (1981); Nambair et al., *Science*, **223**:1299 (1984); Jay et al., *J. Biol. Chem.*, **259**:6311 (1984).

Synthetic DNA sequences allow convenient construction of genes which will express
30 calcium-independent receptor of α -latrotoxin (CIRL) analogs or "muteins".

Alternatively, DNA encoding muteins can be made by site-directed mutagenesis of native calcium-independent receptor of α -latrotoxin (CIRL) genes or CDNAS, and muteins can be made directly using conventional polypeptide synthesis.

- 5 The genes which express CIRL or its analogs or muteins can be utilized in various therapeutic methods. Appropriate vectors for gene delivery are described, for instance, in U.S. Patents Nos. 5,173,414 (Lebkowski *et al.*), 5,139,941 (Muzyezka *et al.*), 4,797,368 (Carter *et al.* and 5,252,479 (Srivasta). These, or other similar viral vectors can be utilized for gene therapy so as to effect expression of CIRL.

10

A general method for site-specific incorporation of unnatural amino acids into proteins is described in Christopher J. Noren, Spencer J. Anthony-Cahill, Michael C. Griffith, Peter G. Schultz, *Science*, **244**:182-188 (April 1989). This method may be used to create analogs with unnatural amino acids.

15

- The present invention extends to the preparation of antisense oligonucleotides and ribozymes that may be used to interfere with the expression of the calcium-independent receptor of α -latrotoxin (CIRL) at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

20

- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. (See Weintraub, 1990; Marcus-Sekura, 1988.) In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when

30

introducing them into calcium-independent receptor of α -latrotoxin (CIRL)-producing cells. Antisense methods have been used to inhibit the expression of many genes *in vitro* (Marcus-Sekura, 1988; Hambor et al., 1988).

- 5 Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that
10 recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, 1988.). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

- Investigators have identified two types of ribozymes, *Tetrahymena*-type and
15 "hammerhead"-type. (Hasselhoff and Gerlach, 1988) *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific
20 mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

- The DNA sequences described herein may thus be used to prepare antisense molecules against, and ribozymes that cleave mRNAs for calcium-independent
25 receptor of α -latrotoxin (CIRL) and their ligands.

- The present invention also relates to a variety of diagnostic applications, including methods for detecting the presence of stimuli such as the earlier referenced polypeptide ligands, by reference to their ability to elicit the activities which are
30 mediated by the present calcium-independent receptor of α -latrotoxin (CIRL). As

mentioned earlier, the calcium-independent receptor of α -latrotoxin (CIRL) can be used to produce antibodies to itself by a variety of known techniques, and such antibodies could then be isolated and utilized as in tests for the presence of particular calcium-independent receptor of α -latrotoxin (CIRL) activity in suspect
5 target cells.

As described in detail above, antibody(ies) to the calcium-independent receptor of α -latrotoxin (CIRL) can be produced and isolated by standard methods including the well-known hybridoma techniques. For convenience, the antibody(ies) to the
10 calcium-independent receptor of α -latrotoxin (CIRL) will be referred to herein as Ab_1 and antibody(ies) raised in another species as Ab_2 .

The presence of calcium-independent receptor of α -latrotoxin (CIRL) in cells can be ascertained by the usual immunological procedures applicable to such
15 determinations. A number of useful procedures are known. Three such procedures which are especially useful utilize either the calcium-independent receptor of α -latrotoxin (CIRL) labeled with a detectable label, antibody Ab_1 labeled with a detectable label, or antibody Ab_2 labeled with a detectable label. The procedures may be summarized by the following equations wherein the asterisk indicates that
20 the particle is labeled, and "CIRL" stands for the calcium-independent receptor of α -latrotoxin:

- A. $CIRL^* + Ab_1 = CIRL^*Ab_1$
B. $CIRL + Ab^* = CIRLAb_1^*$
25 C. $CIRL + Ab_1 + Ab_2^* = CIRLAb_1Ab_2^*$

The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized within the scope of the present invention. The "competitive" procedure, Procedure A, is described in U.S. Patent Nos. 3,654,090
30 and 3,850,752. Procedure C, the "sandwich" procedure, is described in U.S. Patent

Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the "double antibody," or "DASP" procedure.

In each instance, the calcium-independent receptor of α -latrotoxin (CIRL) forms
5 complexes with one or more antibody(ies) or binding partners and one member of the complex is labeled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

10 It will be seen from the above, that a characteristic property of Ab_2 is that it will react with Ab_1 . This is because Ab_1 raised in one mammalian species has been used in another species as an antigen to raise the antibody Ab_2 . For example, Ab_2 may be raised in goats using rabbit antibodies as antigens. Ab_2 therefore would be anti-rabbit antibody raised in goats. For purposes of this description and claims,
15 Ab_1 will be referred to as a primary or anti-calcium-independent receptor of α -latrotoxin (CIRL) antibody, and Ab_2 will be referred to as a secondary or anti- Ab_1 antibody.

The labels most commonly employed for these studies are radioactive elements,
20 enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others.

A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared
25 in goats and conjugated with fluorescein through an isothiocyanate.

The calcium-independent receptor of α -latrotoxin (CIRL) or its binding partner(s) can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The
30 preferred isotope may be selected from 3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe ,

^{90}Y , ^{125}I , ^{131}I , and ^{186}Re .

Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

A particular assay system developed and utilized in accordance with the present invention, is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantity of both the labeled and unlabeled material after which binding studies are conducted to determine the extent to which the labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained.

Accordingly, a purified quantity of the calcium-independent receptor of α -latrotoxin (CIRL) may be radiolabeled and combined, for example, with antibodies or other inhibitors thereto, after which binding studies would be carried out. Solutions would then be prepared that contain various quantities of labeled and unlabeled uncombined calcium-independent receptor of α -latrotoxin (CIRL), and cell samples would then be inoculated and thereafter incubated. The resulting cell monolayers are then washed, solubilized and then counted in a gamma counter for a length of time sufficient to yield a standard error of $<5\%$. These data are then subjected to Scatchard analysis after which observations and conclusions regarding material

activity can be drawn. While the foregoing is exemplary, it illustrates the manner in which a receptor assay may be performed and utilized, in the instance where the cellular binding ability of the assayed material may serve as a distinguishing characteristic.

5

An assay useful and contemplated in accordance with the present invention is known as a "cis/trans" assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a particular receptor of interest when transfected into an appropriate cell line, and the second of which is a
10 plasmid that expresses a reporter such as luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a particular receptor, one of the plasmids would be a construct that results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to the luciferase gene in which the response
15 element to the particular receptor is inserted. If the compound under test is an agonist for the receptor, the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate transcription of the luciferase gene. The resulting chemiluminescence is then measured photometrically, and dose response curves are obtained and compared to those of known ligands. The
20 foregoing protocol is described in detail in U.S. Patent No. 4,981,784 and PCT International Publication No. WO 88/03168, for which purpose the artisan is referred.

In a further embodiment of this invention, commercial test kits suitable for use by a
25 medical specialist may be prepared to determine the presence or absence of calcium-independent receptor of α -latrotoxin (CIRL) activity in suspected target cells. In accordance with the testing techniques discussed above, one class of such kits will contain at least the labeled calcium-independent receptor of α -latrotoxin (CIRL) or its binding partner, for instance an antibody specific thereto, and directions, of
30 course, depending upon the method selected, *e.g.*, "competitive," "sandwich,"

"DASP" and the like. The kits may also contain peripheral reagents such as buffers, stabilizers, *etc.*

Accordingly, a test kit may be prepared for the demonstration of the presence or
5 capability of cells for predetermined calcium-independent receptor of α -latrotoxin (CIRL) activity, comprising:

- (a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of the present calcium-independent receptor of α -latrotoxin (CIRL) factor or a specific binding partner
10 thereto, to a detectable label;
- (b) other reagents; and
- (c) directions for use of said kit.

More specifically, the diagnostic test kit may comprise:

- 15 (a) a known amount of the calcium-independent receptor of α -latrotoxin (CIRL) as described above (or a binding partner) generally bound to a solid phase to form an immunosorbent, or in the alternative, bound to a suitable tag, or plural such end products, *etc.* (or their binding partners) one of each;
- (b) if necessary, other reagents; and
- 20 (c) directions for use of said test kit.

In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol, and comprises:

- (a) a labeled component which has been obtained by coupling the calcium-
25 independent receptor of α -latrotoxin (CIRL) to a detectable label;
- (b) one or more additional reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of:
 - (i) a ligand capable of binding with the labeled component (a);
 - (ii) a ligand capable of binding with a binding partner of the labeled
30 component (a);

(iii) a ligand capable of binding with at least one of the component(s) to be determined; and

(iv) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined; and

- 5 (c) directions for the performance of a protocol for the detection and/or determination of one or more components of a reaction between the calcium-independent receptor of α -latrotoxin (CIRL) and a specific binding partner thereto.

In accordance with the above, an assay system for screening potential drugs
10 effective to modulate the activity of the calcium-independent receptor of α -latrotoxin (CIRL) may be prepared. The calcium-independent receptor of α -latrotoxin (CIRL) may be introduced into a test system, and the prospective drug may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the calcium-independent receptor of α -latrotoxin (CIRL)
15 activity of the cells, due either to the addition of the prospective drug alone, or due to the effect of added quantities of the known calcium-independent receptor of α -latrotoxin (CIRL).

The following examples are presented in order to more fully illustrate the preferred
20 embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

EXAMPLE 1

25 **Two high affinity α -latrotoxin receptors in brain membranes**

In several independent studies, Scatchard plots of the α -latrotoxin binding activity demonstrated the presence of only one binding site (Rosenthal et al., 1990; Meldolesi, 1982; Tzeng and Siekevitz, 1979a). However, the maximum number of the binding sites was reduced by almost 50% in the presence of calcium chelators
30 (Rosenthal et al., 1990; Tzeng and Siekevitz, 1979a). To analyze whether two

receptors of the same affinity exist, or whether there is only one that is partially activated by calcium ions, concanavalin A was used as an antagonist of α -latrotoxin. This lectin inhibits both toxic effects and binding of α -latrotoxin, if it is applied prior to the addition of toxin. The inhibitory effect of Concanavalin A on α -
5 latrotoxin membrane receptors with added calcium ions and with all calcium ions removed by EDTA chelation has been analyzed. The inhibition curves demonstrate a significant difference (approximately 5-fold) in the half-maximum inhibitory effect of Concanavalin A on the calcium-dependent and calcium-independent α -latrotoxin binding sites in brain membranes (see Figure 1).

10

Purification and molecular cloning of CIRL

Affinity chromatography on immobilized α -latrotoxin columns has been used to purify active α -latrotoxin-binding proteins from brain membrane detergent extracts (Scheer and Meldolesi, 1985; Petrenko et al., 1990). Among them, the Mr 200,000
15 and 160,000 proteins were identified as isoforms of calcium-dependent high-affinity α -latrotoxin receptor (Petrenko et al., 1990; Petrenko et al., 1993). A protein band of about 120,000 was also detected in the affinity-purified receptor preparations obtained either in calcium-containing or calcium-deficient buffers. This band showed α -latrotoxin immunoreactivity in Western blotting experiments and therefore
20 was initially identified as α -latrotoxin bleeding from the column (Petrenko et al., 1991; O'Connor et al., 1993). However, partial amino acid sequencing of this protein band produced the sequences which were not homologous to α -latrotoxin or any other protein in current databases (Table 1 below).

TABLE 1. PEPTIDE SEQUENCES OF PURIFIED Mr 120,000 PROTEIN

5	I L M E Q L D I L D A SEQ ID NO: 3	VI S G D N A X N I A S E L M V SEQ ID NO: 8
10	II G I A L F Q Y L P A L G SEQ ID NO: 4	VIIa V P V T P G N L Q K SEQ ID NO: 9
15	III T D G S T E M L S G V D SEQ ID NO: 5	b Y E G N W E T G Y D K SEQ ID NO: 10
20	IV I Y V M P C I P Y R SEQ ID NO: 6	VIII V F L M D P V I F T V A H L E A K SEQ ID NO: 11
25	V S L Q L Y V I N A E V I SEQ ID NO: 7	IX X F A V L M A H R E P E SEQ ID NO: 12

Peptide VII gave two sequences which were called separately on the basis of yield ratios.

On the basis of these partial sequences, DNA probes were designed which were used to isolate overlapping clones from rat brain cDNA libraries (see, Experimental procedures, below). One long open reading frame was detected which encodes a novel protein consisting of 1471 amino acid residues (Figure 2A, SEQ ID NO:1).

The predicted size of the cloned protein was significantly larger than the apparent size of the purified Mr 120,000 protein. The purified receptor proteins were therefore tested to determine whether they contain all of the predicted CIRL sequence by peptide mapping and by analysis with region-specific antibodies. High

resolution mass-spectrometry of trypsin-generated peptides revealed the presence of peptides which were attributable to more than 80% of the deduced protein sequence and distributed in a random manner throughout the whole sequence (data not shown). The antibody against the Mr 120,000 protein immunostained only the band
5 of this size in both purified receptor and brain membranes (V.G. Krasnoperov et al., *Biochem. Biophys. Res. Commun.* **227**, 868-875 (1996).), while the antibody against the 18 amino acid residues closest to the C-terminus failed to recognize the Mr 120,000 protein and instead reacted with a fuzzy band of about 80,000 Da. However, this C-terminal antibody efficiently immunoprecipitated the Mr 120,000
10 protein and α -latrotoxin-binding activity from brain detergent extracts. Altogether, these data suggest that CIRL is originally synthesized as a single polypeptide chain which is later proteolytically processed yielding two complexed subunits, the N-terminal glycosylated Mr 120,000 protein containing most of the extracellular domain and the C-terminal Mr 80,000 fragment which includes the transmembrane
15 core and the intracellular domain. This may resemble the proteolytic processing of LDL receptor-related protein, a large transmembrane receptor known to be composed of two subunits derived from the internal cleavage of a precursor (J. Herz, R. C. Kowal, J. L. Goldstein, M. S. Brown, *EMBO J.* **9**, 1769-1776 (1990)).

20

CIRL is a high affinity receptor of α -latrotoxin

The identity of CIRL as a high-affinity α -latrotoxin binding protein was directly confirmed by transfections of COS cells, a cell line of non-neuronal origin, with an expression plasmid containing CIRL cDNA (The insert of the longest clone (p87-7)
25 encoding full-length protein was subcloned into pcDNA 3.1, a eucaryotic expression vector (Invitrogen). The resulting plasmid was purified by a midi-prep kit (Invitrogen) and used in transfections of COS-7 cells by the calcium phosphate precipitate method. After two day incubation, the cells were harvested in a cold buffer containing 0.1 M Tris-HCl, 2mM EDTA, pH 7.9. The cells were lysed by a
30 freeze-thaw procedure, the membranes were pelleted by centrifugation and used for

α -latrotoxin-binding assay in a calcium-deficient buffer). The transfected COS cells exhibited high-affinity specific binding of radioactive α -latrotoxin in the absence of calcium (180 ± 28 fmol/mg protein in CIRL transfected cells versus 3.9 ± 3.3 in mock transfections). Scatchard plot analysis (Figure 3A) demonstrated that the cells

5 transfected with the CIRL expression construct bound α -latrotoxin with an affinity similar to that of the calcium-independent binding sites in rat brain membranes (calculated $K_d = 0.16$ nM for recombinant receptor, $K_d = 0.28$ nM for brain membranes). Since α -latrotoxin acts extracellularly, the recombinant extracellular domain of CIRL was tested to determine if it by itself would bind α -latrotoxin.

10 COS cells were transfected with the deletion construct encoding the entire extracellular sequence which was expected to get secreted from the transfected cells into the media. The cell conditioned media were further chromatographed on α -latrotoxin-Sepharose and the retained proteins were analyzed by Western blotting with the anti-Mr 120,000 subunit antibody. The immunostaining demonstrated the

15 presence of the band of the expected size (about 120,000 Da) thus confirming interaction of α -latrotoxin with the extracellular portion of CIRL (Figure 3B).

Structural features of CIRL

Database searches using BLAST program (NCBI server) revealed significant

20 homology of the CIRL with three recently discovered orphan receptors (the leukocyte activation antigen CD97, EMR1, an EGF module-containing mucin-like hormone receptor and F4/80, a murine macrophage-restricted cell surface glycoprotein, reference 20), members of the secretin receptor family suggesting that CIRL belongs to the G-protein-coupled receptors superfamily. The hydrophobicity

25 plot of CIRL indicates the presence of seven adjacent hydrophobic segments, potential transmembrane helices, which is a hallmark of serpentine G-protein-coupled receptors. The putative transmembrane regions of CIRL are significantly homologous (about 30% identify and 50-60% similarity) to the transmembrane regions of the orphan receptors and other members of the secretin receptor family

30 (21), e.g. secretin receptor, corticoliberin receptor, calcitonin receptor, diuretic

hormone receptor, VIP receptor, etc. (Fig. 4A). About 10% of amino acid residues in these regions appear to be perfectly conserved among all of the family members. Several other regions of significant homology include the predicted extracellular loops between transmembrane segments I and II, III and IV, IV and V, and a small intracellular region. Two conserved cysteine residues are present in the extracellular loops between segments II and III, and between segments IV and V, that are typical for G-protein-coupled receptors and are thought to form a disulfide bridge on the basis of the structural studies of rhodopsin. Finally, a pair of adjacent cysteines, a potential palmitoylation site, characteristic of G-protein-coupled receptors (Reviewed in H.G. Dohlman, J. Thorner, M.G. Caron, R.J. Lefkowitz, *Ann. Rev. Biochem.* **60**, 653-688 (1991).), is found in the cytoplasmic domain close to the transmembrane segments.

On the basis of the hydrophobicity plot and homology searches, the domain model of CIRL which consists of three major regions was proposed, *i.e.*, the large extracellular N-terminal region, the transmembrane region including seven hydrophobic helices and the intracellular C-terminal region, as shown in Figure 4B. The extracellular domain is proteolytically cleaved somewhere close to the transmembrane helices. This cleavage results in the formation of two subunits that nevertheless does not compromise the integrity of the whole protein. In the very amino terminus of the protein (residues 4-22), CIRL contains a hydrophobic segment, which has the features typical of a secretion signal peptide sequence. This suggests that the amino terminal region of CIRL is located extracellularly which is typical for G-protein-coupled receptors. The most likely site of the signal peptide cleavage is C-terminal to A[21], predicted by sequence homology with known signal peptidase cleavage sites (G. von Heijne, *Nucleic Acids Res.* **14**, 4683-4690 (1986).)

Several domains of a large extracellular domain of CIRL, its Mr 120,000 subunit, show significant homology with a galactose-binding lectin from sea urchin eggs (35% identity and 60% similarity, ref. 23), with olfactomedin, a major building

block in the extracellular matrix of olfactory neuroepithelium (35% identity and 55% similarity), with olfactomedin-related protein (40% identity and 60% similarity, ref. 24), and with mucin. The homology of CIRL's unusually large extracellular domain to these proteins may suggest its possible function in
5 interacting with glycoproteins of the extracellular matrix and/or membrane of neighboring cells.

Brain-specific distribution of CIRL

The tissue distribution of CIRL was analyzed by Northern blotting which showed
10 that the Mr 120,000 protein subunit has a brain-specific distribution. Of seven rat tissues analyzed (brain, liver, heart, lung, kidney, spleen, skeletal muscle and duodenum), only brain shows a specifically hybridized band of approximately 6 kbase. The size of this band is close to the size of the longest clone (5391 base) cloned from the rat brain cDNA library which was full-length with respect to the
15 coding sequence.

To compare CIRL concentrations within several regions of the rat brain, Western blotting with the anti-Mr 120,000 antibody was used. Rat brains were dissected to isolate cortex, cerebellum, hippocampus, thalamus and striatum. Crude membranes
20 were prepared from each tissue and analyzed for both α -latrotoxin-binding activity and CIRL immunoreactivity. The highest concentrations of calcium-independent receptors were found in striatum, somewhat lower in cortex and hippocampus, and much less of these receptors were detected in cerebellum (see Figure 5). Therefore, the distribution of CIRL immunoreactivity was in good agreement with the pattern
25 of calcium-independent α -latrotoxin binding activity, thus supporting CIRL as the calcium-independent brain receptor of α -latrotoxin.

CIRL is a glycoprotein

The analysis of α -latrotoxin activity and binding to the receptors by Concanavalin A
30 suggested that CIRL might be a glycoprotein. The analysis of tryptic peptides of

CIRL by mass spectrometry revealed the presence of mannose-containing glycopeptides. To determine if CIRL is a glycoprotein, it was tested by digestion with three glycosidases, neuraminidase, peptide-N-glycosidase F (PNGase F) and O-glycosidase. Affinity purified CIRL was digested with these enzymes, blotted
5 onto nitrocellulose and immunodecorated with anti-CIRL antibody (Figure 6). Only PNGase F produced a noticeable change in the apparent size of the protein. This confirms that CIRL is a glycoprotein containing N-attached carbohydrate chain(s). This finding is supported by the presence of seven potential N-glycosylation sites in the predicted protein structure. CIRL may be also O-glycosylated in the mucin-like
10 domain. However, if present, O-glycosylation is not as extensive as N-glycosylation and does not significantly change protein mobility on a gel.

CIRL interacts with α -latrotoxin and syntaxin

It had been previously reported that synaptotagmin and syntaxin co-purify with α -
15 latrotoxin receptors in the course of affinity chromatography on α -latrotoxin-Sepharose with calcium-containing buffers when neurexin I α is the major component of the column eluate (Petrenko et al., 1991; O'Connor et al., 1993). To determine if these proteins were also present in the eluate of an α -latrotoxin affinity column when all stages of purification were performed in
20 EDTA-containing buffers so that neurexin I α was not retained, the eluate was tested. Syntaxin and synaptotagmin were detected by Western blotting of the eluted receptor preparations but not other nerve terminal proteins such as synaptophysin, SNAP-25, synapsins, rab 3A, synaptobrevin I and II, and Munc 18/nSec1 (Figure 7A). When the α -latrotoxin affinity column was eluted with a salt gradient,
25 synaptotagmin was found in the beginning of the gradient (0.2-0.3 M salt) (Petrenko et al., 1991) whereas syntaxin co-eluted with CIRL at salt concentrations higher than 0.6 M (Petrenko et al., 1991, and data not shown).

To assure the specificity of complexing of CIRL with α -latrotoxin and syntaxin,
30 anti-syntaxin antibody was tested to determine if it could immunoprecipitate

calcium-independent α -latrotoxin binding activity from detergent extracts of total brain membranes. An antibody against CIRL was included in immunoprecipitation reactions as a positive control. As a negative control, pre-immune serum or normal IgGs were used. Additional controls were included to test whether these antibodies
5 were capable of immunoprecipitating the radiolabel by direct interaction with α -latrotoxin where brain membranes were omitted. After incubations and washes, immunomatrices where anti-CIRL and anti-syntaxin antibodies were adsorbed showed significantly higher retention of labeled α -latrotoxin than the control sorbents (Figure 7B).

10

Although synaptotagmin was found in the preparations of calcium-independent receptors and it was previously reported that the calcium-ion dependent α -latrotoxin stimulation of neurosecretion but not the calcium-dependent one is impaired in synaptotagmin-deficient PC12 cells (Shoji-Kasai *et al.*, 1994), an anti-synaptotagmin
15 antibody that was tested, failed to immunoprecipitate the complex of CIRL with α -latrotoxin in the absence of calcium (data not shown). Therefore, it remains to be seen whether the interaction of synaptotagmin with CIRL and toxin is specific or may reflect a weaker indirect complexing through syntaxin or possibly some other protein.

20

It is generally accepted that α -latrotoxin is a specific presynaptic neurotoxin (Okamoto *et al.*, 1971; Frontali *et al.*, 1976). Its physiological action has been most thoroughly studied in vertebrate neuro-muscular junctions. α -Latrotoxin effects on the neuro-muscular junction consists of two phases. Initially, the frequency of
25 spontaneously released acetylcholine quanta increases dramatically (Clark *et al.*, 1970; Ceccarelli and Hurlbut, 1980; Hurlbut *et al.*, 1990). This effect does not critically depend on the presence of calcium if the buffer contains magnesium ions (Misler and Hurlbut, 1979). Later, the stores of neurotransmitter are exhausted (faster without calcium and slower with calcium) and synaptic transmission ceases
30 (Ceccarelli and Hurlbut, 1980). The poisoned nerve terminals degenerate and this

process is calcium-dependent (Okamoto et al., 1971; Gorio et al., 1978).

Although α -latrotoxin's primary target is the peripheral nervous system, it also acts as a stimulator of neurotransmitter release in *vitro* preparations from the central nervous system, such as brain slices, synaptosomes and cell cultures (Tzeng et al., 1978; Meldolesi et al., 1984; Nicholls et al., 1982; Geppert et al., 1994; McMahon et al., 1990). In these systems, α -latrotoxin acts on different types of synapses and there has been no report suggesting that any particular neurotransmitter cannot be released by α -latrotoxin (Rosenthal and Meldolesi, 1989). Therefore, α -latrotoxin is considered as a universal stimulator of neurotransmitter release (Rosenthal and Meldolesi, 1989). In neuronal cell cultures, it also produces a pronounced morphological change - the beads that appear on the membrane of neuronal processes and may be explained by intense exocytosis (Rubin et al., 1978). Moreover, recently reported α -latrotoxin-stimulated secretion of catecholamines from adrenal chromaffin cells (Barnett et al., 1996) and glutamate from astrocytes (Parpura et al., 1995) suggests that α -latrotoxin sensitivity may not be restricted to neurons and α -latrotoxin may be a secretagogue with a wider spectrum of activity.

While not wishing to be bound by any particular mechanism, mechanisms of neurosecretion stimulation by α -latrotoxin can be proposed. Four such hypotheses have been formulated. One is that α -latrotoxin is an ionophore, *i.e.*, it creates cation-permeable channels in the membrane which results in a calcium influx and subsequent stimulation of secretion (Finkelstein et al, 1976, Grasso et al. 1980). Another possibility is that the toxin stimulates cytoskeletal rearrangements causing exocytosis (Tzeng and Siekevitz, 1979a). A third hypotheses is that by receptor stimulation, secondary messenger signaling is triggered (Vicentini and Meldolesi, 1984; Rosenthal et al. 1990). Finally, there is the possibility that α -latrotoxin acts as a membrane fusion protein (Lishko et al., 1990).

Any of the proposed mechanisms implicate the binding of α -latrotoxin to its

- membrane receptors as a first step. Stimulation of neurotransmitter release by α -latrotoxin have been correlated with its binding to high-affinity membrane receptors (Meldolesi, 1982; Meldolesi et al., 1983). The necessity of binding to specific α -latrotoxin receptors is also supported by existence of Black Widow spider
- 5 neurotoxins which produce the same physiological effect in different species and do not cross-react or compete for the same binding site (Fritz et al., 1980 and data not shown). α -Latrotoxin receptors were detected in the tissues of the nervous system but not in other tissues. Active α -latrotoxin receptors have been purified by affinity chromatography on α -latrotoxin-Sepharose (Scheer and Meldolesi, 1985; Petrenko
- 10 et al., 1990). When brain proteins were loaded on the affinity column in the presence of calcium, the material eluted with an EDTA-containing buffer had two major components, the Mr 160,000 and 200,000 proteins. Both of these proteins bind α -latrotoxin with high affinity in the presence of calcium (Petrenko et al., 1990; Petrenko et al., 1993). They have the same protein structure but different
- 15 carbohydrate modification and belong to the neurexin family of neuron-specific multiply spliced cell surface receptors (Petrenko et al., 1990; Ushkaryov et al., 1992). The extracellular domain of recombinant neurexin Ia binds α -latrotoxin with high affinity in a calcium-dependent manner ($EC_{50} \approx 30$ mM) (Davletov et al., 1995). Since both native and recombinant neurexin Ia require calcium for α -latrotoxin
- 20 binding, this protein is probably not involved in the stimulation of spontaneous neurotransmitter release by α -latrotoxin in the absence of calcium. However, they might be important in mediating the nerve terminal degeneration, a calcium-dependent effect of α -latrotoxin.
- 25 The data from the literature suggest that the key step in α -latrotoxin-stimulated neurosecretion is the one which is not calcium-dependent. Since brain membranes also contain a smaller quantity of α -latrotoxin high affinity binding sites which are active in EDTA buffers, it is possible that these receptor(s) and not neurexin Ia, are involved in calcium-independent stimulation of neurotransmitter release by α -
- 30 latrotoxin. These receptors were tested to determine if they are pharmacologically

different from neurexin I α , using Concanavalin A, a well-characterized antagonist of α -latrotoxin. This lectin effectively inhibits both binding (Meldolesi, 1982) and physiological effects (Grasso et al., 1978; Rubin et al., 1978) of α -latrotoxin, when it is prebound to nerve preparations. It was found that the inhibition of

5 calcium-independent receptors by Concanavalin A was significantly stronger than the inhibition of neurexin I α by the lectin. An analysis of the published data indicates that, in the presence of calcium, Concanavalin A inhibition of α -latrotoxin-stimulated secretion can be achieved at lower concentrations than the complete inhibition of α -latrotoxin binding (Meldolesi, 1982; Grasso et al., 1978;

10 Tzeng and Siekevitz, 1979a; Rubin et al., 1978). This suggests the primary importance of calcium-independent receptors and not neurexins as mediators of α -latrotoxin-stimulated neurosecretion.

We have compared some features of CIRL with the expected features of a putative

15 calcium-independent α -latrotoxin receptor. Firstly, like the calcium-dependent α -latrotoxin receptor, CIRL was detected in brain tissue, but not in a number of other tissues, by Northern and Western blotting. Secondly, the analysis of the distribution of CIRL in brain regions closely correlates with the distribution of the calcium-independent α -latrotoxin-binding activity. Interestingly, unlike calcium-

20 dependent receptors, calcium-independent receptors are more concentrated in the striatum than cortex which coincides with the distribution of CIRL immunoreactivity. CIRL is a glycoprotein that correlates with the known lectin inhibition of both α -latrotoxin activity and receptor binding. Finally, the peptide mixes of the receptor preparations purified by affinity chromatography on α -

25 latrotoxin-Sepharose, did not contain a significant amount of the peptides other than from CIRL according to the mapping by high-resolution mass spectrometry. One cannot be completely rule out the existence of α -latrotoxin-binding homologs or isoforms of CIRL present in lower concentration in the brain or enriched in other secretory tissues. However, all of these data support the idea that CIRL is the

30 major, if not the only, calcium-independent α -latrotoxin receptor.

Previously, the most widely accepted explanation of α -latrotoxin effects was that it acts as an ionophore, creating cation-permeable pores in the membrane which make possible the entry of calcium into the nerve terminal (Grasso *et al.*, *Nature* **283**, 774-776 (1980); Nicholls *et al.*, *Proc. Natl. Acad. Sci. USA* **79**, 7924-7928 (1982); Wanke *et al.*, *Biochem. Biophys. Res. Commun.* **134**, 320-325 (1986); Hurlbut *et al.*, *J. Membr. Biol.* **138**, 91-102 (1994).). This view was largely based on the ability of purified α -latrotoxin to form cation channels in artificial lipid bilayers (Finkelstein *et al.*, *Science* **193**, 1009-1011 (1976); Robello *et al.*, *J. Membr. Biol.* **95**, 55-672 (1987).). The insertion of toxin molecules into the cell membrane, resulting in calcium fluxes through the formed cation channels would be facilitated by binding to any α -latrotoxin receptor, neurexin Ia or CIRL. There is no doubt that calcium fluxes through α -latrotoxin channels are a significant component of the toxin's effects and may be primarily responsible for calcium-dependent nerve terminal degeneration. However, this mechanism would be effectively eliminated in calcium-free media while the robust stimulation of spontaneous neurotransmitter release by α -latrotoxin will still persist. Our data suggest the potential importance of a second mechanism in α -latrotoxin action which involves intracellular signaling through G-proteins. In support of this hypothesis, α -latrotoxin effects were found to be inhibited by agonists of GABA_A and μ -opioid receptors, which are G-protein-linked receptors.

GTP is known to be an important molecule involved in exocytosis. However, its role has been largely attributed to its interaction with small GTP-binding proteins of the Rab family. Although heterotrimeric G-proteins have been implicated in regulation of neurosecretion by presynaptic receptors, most of them inhibit neurosecretion. Since CIRL is a target of α -latrotoxin, a strong stimulator of neurosecretion, it is believed that the physiological CIRL may be important in regulating exocytosis and/or endocytosis.

Based on their structural characteristics, endogenous ligands of CIRL can thus be

used to modulate and regulate neurotransmitter release and produce α -latrotoxin-like effects on the nerve terminal.

Experimental procedures

- 5 α -Latrotoxin was purified from lyophilized Black Widow Spider venom glands and radioactively labeled with ¹²⁵I by chloramine T procedure as previously described (Petrenko et al., 1990). The α -latrotoxin binding activity was analyzed by the rapid centrifugation assay (Davletov et al., 1995). SDS-PAGE and Western blotting with ECL detection were performed according to Bio-Rad and Amersham protocols,
10 respectively. Northern blotting was done with a premade multiple tissue blot (Bios Laboratories) according to the manufacturer's protocol with a randomly labeled probe (Boehringer-Mannheim) obtained with a full-length CIRC cDNA fragment.

Protein purification and peptide sequencing

- 15 The purification procedure was carried out at 4°C. Approximately 18-25 frozen rat brains (50g) were homogenized in 1 liter of 20 mM Tris-HCl, pH 7.9, 150 mM NaCl, 2 mM EDTA and 0.1 mM PMSF buffer using a Waring blender for 90 seconds and centrifuged at 10,000g for 30 minutes. The pellet was resuspended in a glass-teflon homogenizer in 420 ml of the buffer containing 20 mM Tris-HCl, 2 mM
20 EDTA, 0.1 mM PMSF, and 2% Triton X-100. After 30-45 minutes incubation, the insoluble material was pelleted at 100,000g for 1 hour. A 300-350 ml aliquot of supernatant was supplemented with 5 M NaCl to a final concentration of 100 mM, and loaded onto 10 ml of the α -latrotoxin-Sepharose column at 0.30-0.35 ml/minutes. After washing the column with 600 ml of 20 mM Tris-HCl, 130 mM
25 NaCl, 2 mM EDTA, and 0.1% Triton X-100, the proteins were eluted with 100 ml of 20 mM Tris-HCl, 1.5 M NaCl, 0.1% Triton X-100 and 2 mM EDTA at a flow rate 0.3 ml/minutes. The eluted receptor proteins were electrophoresed on a 10% SDS gel, transferred to immobilon membrane and digested with trypsin. The digest mixture was then fractionated with a size exclusion column, using the buffer
30 containing 50 % acetonitrile and 0.2 % TFA. Each fraction was further fractionated

using a C18 one millimeter micropore HPLC column and a 50 minute linear binary gradient running from 5% buffer B to 90% buffer B (buffer A = 2% acetonitrile and 0.09% TFA, buffer B = 90% acetonitrile and 0.10% TFA). The flow rate through the column was 50 microliters per minute. The HPLC system used was a

5 Michrome Bioresources Ultrafast Protein Analyzer equipped with a fixed wavelength ($\lambda = 214$ nm) ultraviolet detector. Fractions corresponding to peaks from the ultraviolet detector were analyzed by matrix assisted laser desorption mass spectrometry (Beavis and Chait, 1996). The mass spectra were used to determine how many peptides were contained in the relevant fractions. Fractions with

10 sufficient purity were then loaded onto a polybrene membrane and analyzed using a Perkin-Elmer Procise peptide microsequencer (pulsed-liquid method). The sequences were determined by comparing the results of the automated sequence calling feature of the Procise data system and the results of manual sequence calling. The sequences obtained were then compared with the mass spectra of the

15 appropriate fraction. Once a sequence was verified, it was compared to all known protein and DNA sequences using the BLAST server at NCBI.

Antibodies

Chickens (egg laying hens) were immunized with affinity purified CIRL additionally

20 purified by preparative gel electrophoresis. The antigen solution was mixed with an equal volume of complete Freund's adjuvant and injected subcutaneously in multiple sites. Two boosters followed the initial injection within two week intervals using incomplete Freund's adjuvant. In two weeks after the last boost, the chickens were bled and the serum was used in Western blotting to test the immune response. Eggs

25 were collected daily and used for the purification of chicken egg yolk immunoglobulins (IgY) according to the established procedure (Carroll and Stollar, 1983). The titer and specificity of antibodies was tested in Western blotting with purified CIRL and total brain membranes. The purified antibody stained on protein band of the Mr 120,000 in total brain membranes. However, it did not inhibit α -

30 latrotoxin binding to CIRL indicating that the site of the α -latrotoxin binding was

not a strong immunogen probably because it is highly conserved in vertebrates.

Cloning and sequencing of CIRL

Molecular cloning experiments were performed according to established procedures and protocols (Ushkaryov et al., 1992, Petrenko et al., 1996). The sequence of a 17 residue peptide VFLMDPVIFTVAHLEAK SEQ ID NO: 11, confirmed by mass spectrometry (1930.3 Da), was used to design two degenerate PCR primers. PCR reactions on a rat cDNA random-primed library, resulted in the isolation of a cDNA fragment of the necessary size. This fragment was used as a template in a PCR reaction with ^{32}P -dCTP to generate a probe for the library screening. About 10 overlapping clones were isolated that encoded most of the protein structure. The most 5'-extended clone was randomly labeled and used to screen an oligo-dT-primed rat brain cDNA which resulted in the isolation of a number of clones, one of them was full-length with respect to the coding cDNA. The clones were sequenced by dideoxy automated method using synthetic primers. Several overlapping clones were sequenced completely on both strands.

Cell transfection assays

The insert of the longest clone (p87-7) encoding full-length protein was subcloned into pcDNA 3.1, a eucaryotic expression vector (Invitrogen). The resulting plasmid was purified by a midi-prep kit (Invitrogen) and used in transfections of COS cells by the calcium phosphate precipitate method. After a two day incubation, the cells were harvested in a cold buffer containing 0.1 M Tris-HCl, 2 mM EDTA, pH 7.9. The cells were lysed by a freeze-thaw procedure, the membranes were pelleted by centrifugation and used for α -latrotoxin-binding assay in a calcium-deficient buffer. The transfected cells were also analyzed by Western blotting with anti-CIRL antibody.

For the analysis of secondary messenger signaling, COS-7 cells were cultured in Dulbecco's modified Eagle medium containing 10% fetal calf serum under 5% CO_2

at 37°C. For transfection, the cells were seeded into 24-well plates at a density of 1×10^5 cells/well the day before transfection. the media were removed the next day and 0.25 ml of Opti-MEM (Life Technology) containing 2 μ l of lipofectamine (Life Technology) and 0.5 μ g of plasmid DNA were added to each well. Five hours later
5 the transfection media were replaced with the culture media. The cells were further labeled with 10 μ Ci/ml of myo-[2- 3 H]inositol on the following day and the levels of inositol phosphates were determined one day later as previously described with slight modification. The modification was that phosphate buffered saline (no Ca^{2+} and Mg^{2+}) was used during the ligand stimulation. All the cDNAs used in these
10 studied were constructed in the expression vectors driven by the CMV promoters.

Immunoprecipitation reactions

About 3g of rat brain was homogenized in 30ml of 20mM Tris HCl, 150mM NaCl, 2mM EDTA, 0.1mM PMSF, pH 7.9 and centrifuged at 50,000 g for 20 minutes.
15 The pellet was resuspended in 30 ml of 20mM Tris HCl, 2mM EDTA, 0.1mM PMSF, and 2% Triton X-100. After 40 minutes incubation at 4°C the mixture was centrifuged at 100,000 x g for 1 hour. 125 I- α -Latrotoxin was added to 1.4 ml portions of supernatant, followed by the addition of antibody after 30 minutes. The mixtures were incubated for 2 hours and further absorbed on Protein A Sepharose
20 over night with gentle rotation. The immunoprecipitation reactions were pelleted, the matrices were washed and counted in the gamma-counter.

The following is a list of documents related to the above disclosure and particularly to the experimental procedures and discussions. The documents should be
25 considered as incorporated by reference in their entirety.

Barnett *et al.* (1996). Single Cell Measurements of Quantal Secretion Induced by α -Latrotoxin from Rat Adrenal Chromaffin Cells: Dependence on Extracellular Ca^{2+} . *Eur. J. Physiology-Pfluegers Archiv.* (in press).

- Beavis *et al.* (1996) in *Methods in Enzymology*, eds. B. L. Karger and W. S. Hancock, 270A, 519-551.
- Carroll *et al.* (1983). Antibodies to calf thymus RNA polymerase II from egg yolks
5 of immunized hens. *J. Biol. Chem.* 258, 24-26.
- Ceccarelli *et al.* (1979). Freeze-fracture studies of frog neuromuscular junctions during intense release of neurotransmitter. I. Effects of black widow spider venom and Ca^{2+} -free solutions on the structure of the active zone. *J. Cell Biol.* 81,
10 163-177.
- Ceccarelli *et al.* (1980). Ca^{2+} -dependent recycling of synaptic vesicles at the frog neuromuscular junction. *J. Cell Biol.* 87, 297-303.
- 15 Clark *et al.* (1970). Effects of black widow spider venom on the frog neuromuscular junction. Effects on the fine structure of the frog neuromuscular junction. *Nature* 225, 703-705.
- Davletov, *et al.*, (1995). High affinity binding of alpha-latrotoxin to recombinant
20 neurexin Ia. *J. Biol. Chem.* 270, 23903-23905.
- Davletov *et al.*, (1996) *J. Biol Chem.* 271, 23239-23245.
- Dohlman *et al.* (1991). Model systems for the study of
25 seven-transmembrane-segment receptors. *Ann. Rev. Biochem.* 60, 653-688.
- Finkelstein *et al.* (1976). Black widow spider venom: effect of purified toxin on lipid bilayer membranes. *Science* 193, 1009-1011.
- 30 Fritz *et al.* (1980). Different components of black widow spider venom mediate

transmitter release at vertebrate and lobster neuromuscular junctions. *Nature* 283, 486-487.

- Frontali *et al.* (1976). Purification from black widow spider venom of a protein
5 factor causing the depletion of synaptic vesicles at neuromuscular junctions. *J. Cell Biol.* 68, 462-479.

Geppert *et al.* (1994). Synaptotagmin I: a major Ca^{2+} sensor for transmitter release
at a central synapse. *Cell* 79, 717-727.

10

Gorio *et al.* (1978). Double mode of action of black widow spider venom on frog
neuromuscular junction. *J. Neurocytology* 7, 193-202.

- Grasso *et al.* (1978). Concanavalin A blocks black widow spider toxin stimulation
15 of transmitter release from synaptosomes. *FEBS Lett.* 85, 241-244.

Grasso *et al.* (1980). Black widow spider toxin-induced calcium fluxes and
transmitter release in a neurosecretory cell line. *Nature* 283, 774-776.

- 20 Grasso *et al.* (1993). The secretion of amino acid transmitters from cerebellar
primary cultures probed by α -latrotoxin. *Neuroscience*. 54, 595-604.

Hurlbut *et al.* (1990). Correlation between quantal secretion and vesicle loss at the
frog neuromuscular junction. *J. Physiol. - London* 425, 501-526.

25

Hurlbut *et al.* (1994). Alpha-latrotoxin channels in neuroblastoma cells. *J. Membr.
Biol.* 138, 91-102.

- 30 Krasnoperov *et al.*, (1996), *Biochem. Biophys. Res. Commun.*, 227:868-875.

- Li *et al.* (1995). Ca^{2+} -dependent and -independent activities of neural and non neural synaptotagmins. *Nature* 375, 594-599.
- Linial *et al.* (1995). α -latrotoxin is a potent inducer of neurotransmitter release in Torpedo electric organ-functional and morphological characterization. *Eur. J. Neurosci.* 7, 42-52.
- Lishko *et al.* (1990). Fusion of negatively charged phospholipid vesicles by alpha-latrotoxin. *FEBS Lett.* 266, 99-101.
- 10 Malgaroli *et al.* (1989). Distribution of alpha latrotoxin receptor in the rat brain by quantitative autoradiography: comparison with the nerve terminal protein, synapsin I. *Neuroscience* 32, 393-404.
- 15 McMahon *et al.* (1990). Alpha-latrotoxin releases both vesicular and cytoplasmic glutamate from isolated nerve terminals. *J. Neurochem.* 55, 2039-2047.
- Meldolesi, J. (1982). Studies on alpha-latrotoxin receptors in rat brain synaptosomes: correlation between toxin binding and stimulation of transmitter release. *J. Neurochem.* 38, 1559-1569.
- 20 Meldolesi *et al.* (1983). The effect of alpha-latrotoxin on the neurosecretory PC12 cell line: studies on toxin binding and stimulation of transmitter release. *Neuroscience* 10, 997-1009.
- 25 Meldolesi *et al.* (1984). Free cytoplasmic Ca^{2+} and neurotransmitter release: studies on PC12 cells and synaptosomes exposed to alpha-latrotoxin. *Proc. Natl. Acad. Sci. USA* 81, 620-624.
- 30 Misler *et al.* (1979). Action of black widow spider venom on quantized release of

- acetylcholine at the frog neuromuscular junction: dependence upon external Mg^{2+} .
Proc. Natl. Acad. Sci. USA 76, 991-995.
- Nicholls *et al.* (1982). α -latrotoxin of black widow spider venom depolarizes the
5 plasma membrane, induces massive calcium influx, and stimulates transmitter
release in guinea pig brain synaptosomes. Proc. Natl. Acad. Sci. USA 79,
7924-7928.
- O'Connor *et al.* (1993). On the structure of the 'synaptosecretosome'. Evidence for
10 a neurexin/synaptotagmin/syntaxin/ Ca^{2+} channel complex. FEBS Lett. 326,
255-260.
- Okamoto *et al.* (1971). Destruction of mammalian motor nerve terminals by black
widow spider venom. Science 172, 733-736.
- 15 Parpura *et al.* (1995). α -latrotoxin stimulates glutamate release from cortical
astrocytes in cell culture. FEBS Letters. 360, 266-70.
- Petrenko *et al.* (1990). Isolation and properties of the α -latrotoxin receptor.
20 EMBO J. 9, 2023-2027.
- Petrenko *et al.* (1991). Binding of synaptotagmin to the α -latrotoxin receptor
implicates both in synaptic vesicle exocytosis. Nature 353, 65-68.
- 25 Petrenko, A.G. (1993). α -Latrotoxin receptor. Implications in nerve terminal
function. FEBS Lett 325, 81-85#.
- Petrenko *et al.* (1993). Polypeptide composition of the α -latrotoxin receptor.
High affinity binding protein consists of a family of related high molecular weight
30 polypeptides complexed to a low molecular weight protein. J. Biol. Chem. 268,

1860-1867.

Petrenko *et al.* (1996). Structure and Evolution of Neurexophilin. *J. Neurosci.* 16, 4360-4369.

5

Puschel *et al.* (1995). Neurexins are differentially expressed in the embryonic nervous system of mice. *J. Neurosci.* 15, 2849-2856.

Robello *et al.* (1987). Permeation of divalent cations through alpha-latrotoxin
10 channels in lipid bilayers: steady-state current-voltage relationships. *J. Membr. Biol.* 95, 55-62.

Rosenthal *et al.* (1990). Mode of action of alpha-latrotoxin: role of divalent cations
in Ca²(+)-dependent and Ca²(+)-independent effects mediated by the toxin. *Mol.*
15 *Pharmacol.* 38, 917-923.

Rosenthal *et al.* (1989). Alpha-latrotoxin and related toxins. *J. Pharmacol. Ther.* 42, 115-134.

20 Rubin *et al.* (1978). Effect of concanavalin A on black widow spider venom activity
at the neuromuscular junction: implications for mechanisms of venom action. *Brain*
Res. 143, 107-124.

Scheer *et al.* (1985). Purification of the putative alpha-latrotoxin receptor from
25 bovine synaptosomal membranes in an active binding form. *EMBO J.* 4, 323-327.

Sher *et al.* (1988). Intracellular calcium homeostasis in a human neuroblastoma cell
line: modulation by depolarization, cholinergic receptors, and alpha-latrotoxin.
Journal of Neurochemistry 50, 1708-1713.

30

- Sher *et al.* (1989). Human neuroblastoma cells acquire regulated secretory properties and different sensitivity to Ca^{2+} and alpha-latrotoxin after exposure to differentiating agents. *Journal of Cell Biology* 108, 2291-2300.
- 5 Shoji-Kasai *et al.* (1994). Synaptotagmin I is essential for Ca^{2+} -independent release of neurotransmitter induced by alpha-latrotoxin. *FEBS Letters* 353, 315-318.
- Tzeng *et al.* (1978). Release of neurotransmitters and depletion of synaptic vesicles in cerebral cortex slices by alpha-latrotoxin from black widow spider venom. *Proc. Natl. Acad. Sci. USA* 75, 4016-4020.
- 10 Tzeng *et al.* (1979a). The binding interaction between alpha-latrotoxin from black widow spider venom and a dog cerebral cortex synaptosomal membrane preparation. *J. Neurochem.* 33, 263-274.
- 15 Tzeng *et al.* (1979b). Action of alpha-latrotoxin from black widow spider venom on a cerebral cortex preparation: release of neurotransmitters, depletion of synaptic vesicles, and binding to membrane. *Adv. in Cytopharmacol* 3, 117-127.
- 20 Ushkaryov *et al.* (1992). Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. *Science* 257, 50-56.
- Valtorta *et al.* (1984). Specific localization of the alpha-latrotoxin receptor in the nerve terminal plasma membrane. *Journal of Cell Biology* 99, 124-132.
- 25 Vicentini *et al.* (1984). alpha Latrotoxin of black widow spider venom binds to a specific receptor coupled to phosphoinositide breakdown in PC12 cells. *Biochem. Biophys. Res. Commun.* 121, 538-544.

Wanke et al. (1986). alpha Latrotoxin of the black widow spider venom opens a small, non-closing cation channel. *Biochem. Biophys. Res. Commun.* 134, 320-325.

While the invention has been described and illustrated herein by references to
5 various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and procedures selected for that purpose. Numerous variations of such details can be implied as will be appreciated by those skilled in the art.

WHAT IS CLAIMED IS:

- 1 1. A calcium-independent receptor of α -latrotoxin (CIRL) comprising a
2 material selected from the group consisting of a protein, active fragments thereof,
3 agonists thereof, mimics thereof, and combinations thereof, said receptor binding α -
latrotoxin (α -LTx) both in the presence or absence of calcium.
- 1 2. The calcium-independent receptor of α -latrotoxin (CIRL) of Claim 1 which
2 has an apparent molecular weight of Mr 200,000 and which is a member of the G-
protein-coupled receptor family.
- 1 3. The calcium-independent receptor of α -latrotoxin (CIRL) of Claim 1 which
is membrane-derived in origin.
- 1 4. The calcium-independent receptor of α -latrotoxin (CIRL) of Claim 1 which
2 is a polypeptide having an amino acid sequence of SEQ ID NO:1.
- 1 5. The calcium-independent receptor of α -latrotoxin (CIRL) of Claim 1 which
is derived from mammalian cells.
- 1 6. An antibody to a calcium-independent receptor of α -latrotoxin (CIRL), the
2 calcium-independent receptor of α -latrotoxin (CIRL) to which said antibody is
raised binding α -latrotoxin (α -LTx) both in the presence or absence of calcium.
7. The antibody of Claim 6 which is a polyclonal antibody.
8. The antibody of Claim 6 which is a monoclonal antibody.
- 1 9. An immortal cell line that produces a monoclonal antibody according to

Claim 8.

- 1 10. A DNA sequence or degenerate variant thereof, which encodes a calcium-
2 independent receptor of α -latrotoxin (CIRL), or a fragment thereof, selected from
3 the group consisting of:
- 4 (A) the DNA sequence of FIGURE 2B (SEQ ID NO:2);
5 (B) DNA sequences that hybridize to any of the foregoing DNA
6 sequences under standard hybridization conditions; and
7 (C) DNA sequences that code on expression for an amino acid sequence
encoded by any of the foregoing DNA sequences.
- 1 11. A recombinant DNA molecule comprising a DNA sequence or degenerate
2 variant thereof, which encodes a calcium-independent receptor of α -latrotoxin
3 (CIRL), or a fragment thereof, selected from the group consisting of:
- 4 (A) the DNA sequence of FIGURE 2B (SEQ ID NO:2);
5 (B) DNA sequences that hybridize to any of the foregoing DNA
6 sequences under standard hybridization conditions; and
7 (C) DNA sequences that code on expression for an amino acid sequence
encoded by any of the foregoing DNA sequences.
- 1 12. The recombinant DNA molecule of Claim 11, wherein said DNA sequence is
operatively linked to an expression control sequence.
- 1 13. The recombinant DNA molecule of Claim 12, wherein said expression
2 control sequence is selected from the group consisting of the early or late promoters
3 of SV40 or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC*
4 system, the major operator and promoter regions of phage λ , the control regions of
5 fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid
phosphatase and the promoters of the yeast α -mating factors.

- 1 14. A probe capable of screening for the calcium-independent receptor of α -
2 latrotoxin (CIRL) in alternate species prepared from the DNA sequence of Claim
10.
- 1 15. A host transformed with a recombinant DNA molecule comprising a DNA
2 sequence or degenerate variant thereof, which encodes a calcium-independent
3 receptor of α -latrotoxin (CIRL), or a fragment thereof, selected from the group
4 consisting of:
5 (A) the DNA sequence of FIGURE 2B (SEQ ID NO:2);
6 (B) DNA sequences that hybridize to any of the foregoing DNA
7 sequences under standard hybridization conditions; and
8 (C) DNA sequences that code on expression for an amino acid sequence
9 encoded by any of the foregoing DNA sequences;
10 wherein said DNA sequence is operatively linked to an expression control
sequence.
- 1 16. The host of Claim 15 wherein the host is selected from the group consisting
2 of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, yeasts, CHO, R1.1, B-W, L-M,
3 COS, BSC1, BSC40, and BMT10 cells, plant cells, insect cells, mammalian cells
and human cells in tissue culture.
- 1 17. A method for detecting the presence or activity of a calcium-independent
2 receptor of α -latrotoxin (CIRL), said calcium-independent receptor of α -latrotoxin
3 (CIRL) binding α -latrotoxin (α -LTx) both in the presence or absence of calcium;
4 wherein said calcium-independent receptor of α -latrotoxin (CIRL) is measured by:
5 A. contacting a biological sample from a mammal in which the
6 presence or activity of said calcium-independent receptor of α -latrotoxin (CIRL) is
7 suspected with a binding partner of said calcium-independent receptor of α -
8 latrotoxin (CIRL) under conditions that allow binding of said calcium-independent
9 receptor of α -latrotoxin (CIRL) to said binding partner to occur; and

10 B. detecting whether binding has occurred between said calcium-
11 independent receptor of α -latrotoxin (CIRL) from said sample and the binding
12 partner;

13 wherein the detection of binding indicates that presence or activity of said
14 calcium-independent receptor of α -latrotoxin (CIRL) in said sample.

1 18. A method for detecting the presence and activity of a calcium-independent
2 receptor of α -latrotoxin (CIRL) associated with a neurological disease in mammals
3 comprising detecting the presence or activity of a calcium-independent α -latrotoxin
4 receptor according to the method of Claim 18, wherein detection of the presence or
5 activity of the calcium-independent α -latrotoxin receptor indicates the presence and
of a neurological or peripheral neuromuscular disease.

1 19. The method of Claim 18 wherein said neurological disease is schizophrenia,
2 Alzheimer's disease, epilepsy, stress disorder, Huntington's disease, or Parkinson's
disease.

1 20. The method of Claim 18 wherein said peripheral neuromuscular disease is
myasthenia gravis.

1 21. A method of testing the ability of a drug or other entity to modulate the
2 activity of a calcium-independent receptor of α -latrotoxin (CIRL) which comprises
3

4 A. culturing a colony of test cells which has the calcium-independent
5 receptor of α -latrotoxin (CIRL) in a growth medium;

6 B. adding the drug under test; and

 C. measuring the reactivity of said drug on said colony of test cells.

1 22. An assay system for screening drugs and other agents for ability to modulate
2 the production and/or activity of a calcium-independent receptor of α -latrotoxin

3 (CIRL), comprising:

4 A. culturing an observable cellular test colony inoculated with a drug or
5 agent; and

6 B. examining said test colony for the presence of said calcium-
7 independent receptor of α -latrotoxin (CIRL) wherein an increase or a decrease in the
8 amount of said calcium-independent receptor of α -latrotoxin (CIRL) indicates the
9 ability of a drug to modulate the production and/or the activity of said calcium-
10 independent receptor of α -latrotoxin (CIRL), said calcium-independent receptor of
11 α -latrotoxin (CIRL) binding α -latrotoxin (α -LTx) both in the presence or absence of
calcium.

1 23. A test kit for the demonstration of a calcium-independent receptor of α -
2 latrotoxin (CIRL) in a eukaryotic cellular sample, comprising:

3 A. a predetermined amount of a detectably labelled specific binding
4 partner of a calcium-independent receptor of α -latrotoxin (CIRL), said calcium-
5 independent receptor of α -latrotoxin (CIRL) binding α -latrotoxin (α -LTx) both in
6 the presence or absence of calcium;

7 B. other reagents; and

C. directions for use of said kit.

1 24. A method of preventing and/or treating cellular debilitations, derangements
2 and/or dysfunctions and/or other disease states in mammals, comprising
3 administering to a mammal a therapeutically effective amount of a material selected
4 from the group consisting of a calcium-independent receptor of α -latrotoxin (CIRL),
5 expressing cells thereof, an agent capable of promoting the production and/or
6 activity of said calcium-independent receptor of α -latrotoxin (CIRL), an agent
7 capable of mimicking the activity of said calcium-independent receptor of α -
8 latrotoxin (CIRL), an agent capable of inhibiting the production of said calcium-
9 independent receptor of α -latrotoxin (CIRL), and mixtures thereof, or a specific
10 binding partner thereto, said calcium-independent receptor of α -latrotoxin (CIRL)

binding α -latrotoxin (α -LTx) both in the presence or absence of calcium.

- 1 25. The method of Claim 24 wherein said disease states include neurological
dysfunctions.
- 1 26. The method of Claim 24 wherein said cells which express calcium-
2 independent receptor of α -latrotoxin (CIRL) are administered to modulate the course
of therapy.
- 1 27. A pharmaceutical composition for the treatment of cellular debilitation,
2 derangement and/or dysfunction in mammals, comprising:
3 A. a therapeutically effective amount of a material selected from the
4 group consisting of a calcium-independent receptor of α -latrotoxin (CIRL),
5 expressing cells thereof, an agent capable of promoting the production and/or
6 activity of said calcium-independent receptor of α -latrotoxin (CIRL), an agent
7 capable of mimicking the activity of said calcium-independent receptor of α -
8 latrotoxin (CIRL), an agent capable of inhibiting the production of said calcium-
9 independent receptor of α -latrotoxin (CIRL), and mixtures thereof, or a specific
10 binding partner thereto, said calcium-independent receptor of α -latrotoxin (CIRL)
11 binding α -latrotoxin (α -LTx) both in the presence or absence of calcium; and
B. a pharmaceutically acceptable carrier.
- 1 28. A calcium-independent receptor of α -latrotoxin (CIRL) implicated in
2 neurological disturbances in mammals, said calcium-independent receptor of α -
3 latrotoxin (CIRL) binding α -latrotoxin (α -LTx) both in the presence or absence of
calcium.
- 1 29. A recombinant virus transformed with the DNA molecule, or a derivative or

fragment thereof, in accordance with Claim 10.

- 1 30. A method of determining the calcium-independent receptor of α -latrotoxin
2 (CIRL)-related pharmacological activity of a compound comprising:
3 administering the compound to a mammal;
4 determining the level and/or activity of calcium-independent receptor of α -
5 latrotoxin (CIRL) proteins present; and
6 comparing the level and/or activity of calcium-independent receptor of α -
latrotoxin (CIRL) to a standard.
- 1 31. The recombinant DNA molecule of Claim 11 comprising plasmid pGEX-3X,
clone E3 or plasmid pGEX-3X, clone E4.
- 1 32. An antisense nucleic acid against a calcium-independent receptor of α -
2 latrotoxin (CIRL) mRNA comprising a nucleic acid sequence hybridizing to said
mRNA.
33. The antisense nucleic acid of Claim 32 which is RNA.
34. The antisense nucleic acid of Claim 32 which is DNA.
- 1 35. The antisense nucleic acid of Claim 32 which binds to the initiation codon of
any of said mRNAs.
- 1 36. A recombinant DNA molecule having a DNA sequence which, on
2 transcription, produces an antisense ribonucleic acid against a calcium-independent
3 receptor of α -latrotoxin (CIRL) mRNA, said antisense ribonucleic acid comprising
an nucleic acid sequence capable of hybridizing to said mRNA.
- 1 37. A calcium-independent receptor of α -latrotoxin (CIRL)-producing cell line

transfected with the recombinant DNA molecule of Claim 36.

- 1 38. A method for creating a cell line which expresses a calcium-independent
2 receptor of α -latrotoxin (CIRL), comprising transfecting a calcium-independent
3 receptor of α -latrotoxin (CIRL)-producing cell line with a recombinant DNA
molecule of Claim 11.
- 1 39. A ribozyme that cleaves calcium-independent receptor of α -latrotoxin (CIRL)
mRNA.
40. The ribozyme of Claim 39 which is a *Tetrahymena*-type ribozyme.
41. The ribozyme of Claim 39 which is a Hammerhead-type ribozyme.
- 1 42. A recombinant DNA molecule having a DNA sequence which, upon
transcription, produces the ribozyme of Claim 39.
- 1 43. A calcium-independent receptor of α -latrotoxin (CIRL)-producing cell line
transfected with the recombinant DNA molecule of Claim 36.
- 1 44. A method for creating a cell line which exhibits reduced expression of a
2 calcium-independent receptor of α -latrotoxin (CIRL), comprising transfecting a
3 calcium-independent receptor of α -latrotoxin (CIRL)
-producing cell line with the recombinant DNA molecule of Claim 36.




Figure 1

MARLAAALWSLCVTTVLVTSATQGLSRAGLPFGLMRRELACEGYPIELRC 50
 PGSDVIM/ENANYGRDDDKICDADPFQMENTVQCYPDAFKIMSQRNNRT 100
 QCVVAGSDAFPDPCPGTYKYLEVQYDCVPYKVEQKVFVCPGTLQKVLEP 150
 TSTHESEHQSGAWCKDPLQAGDRIYVMPWIPYRTDTLTEYASWEDYVAAR 200
 HTTYRLPNRVDTGTGFVVDGAVFYNKERTRNIVKYDLRTRIKSGETVIN 250
 TANYHDTSPYRWGGKTDIDLAVDENGWLVIYATEGNNGRLVVSQNLNPLYTL 300
 RFEGTWE~~TGYDKRSASNAFMVCGVLYVLR~~SVYVDDDSEAAGNRVDYAFNT 350
 NANREEFVSLAFPNPYQFVSSVDYNPRDNQLYVWNNYFVVRYSLFEGPPD 400
 PSAGPATSPPLSTTTTARPTPLTSTASPAATPLRRAPLTTHPVGAINQL 450
 GPDLPATAPAPSTRRPPAPNLHVSPELFCEPREVRRVQWPATQQGMLVE 500
 RPCPKGTRGIA~~SFOCLPALGLWN~~PRGPDLSNCTSPWVNQVAQKIKSGENA 550
 ANIASELARHTRGSIYAGDVSSSVKLMEQLLDILDAQLQALRPIERESAG 600
 KNYNKM~~HKRERTCKDYIKAV~~VETVDNLLRPEALESWKDMNATEQVHTATM 650
 LLDVLEE~~GAFLLADNV~~REPARFLAAKQNVVLEVTVLSTEGQVQELVFPQE 700
 YASESSIQLSANTIKQNSRNGVVKVVFILYNNLGLFLSTENATVKLAGEA 750
 GTGGPGGASLVVNSQVIAASINKESSRVFLMDPVIFTVAHLEAKNHFNAN 800
 CSFWNYSERSMLGYWSTQGCRLVESNKTHTTCACSHLTNFAVLMAHREIY 850
 QGRINELL~~SVITWVGIVISLV~~CLAICISTFCFLRGLQTDNRNTIHKNLCI 900
 NLFLAELLFLVGIDKTQYEVACPIFAGLLHYFFLA~~AFSWLC~~LEGVHLYLL 950
 LVEVFESEYSRTKY~~YYLGGYCF~~PALVVGIAAAIDYRSYGTEKACWLRVDN 1000
 YFIWSFIGPVSFVIVVNLVFLMVTLHKMIRSSSVLKPDSRLDN~~IKSWAL~~ 1050
 GAIAL~~LFLGLTWAFGLLF~~INKESVVMAYLFTTFNAFQGVFIFVFHCA~~LQ~~ 1100
 KKVHKEYSKCLRHSYCCIRSPPGGAHGS~~LKTSAMRSNTRY~~YTGTSRIRR 1150
 MWNDTV~~RKQTESSFMAGDINST~~PTLN~~RGTMGNHLLTN~~PVLQPRG~~GTSPYN~~ 1200
 TLIAESVGFNPSSPPVFNSPGSYREPKHPLGGREACGMDTLPLNGNFNNS 1250
 YSLRSGDFPPGDGPEPPRGRNLADAAFEKMIISELVHNNLRGASGGAK 1300
 GPPPEPPVPPVPGVSEDEAGGPGGADRAEIELLYKALEEPLLLPRAQSVL 1350
 YQSDLDESE~~SCTAEDGATSRPLSSPPGR~~DSLYASGANLRDSPSYPDSSPE 1400
 GPNEALPPPPAPP~~GPPEIYYTSRPPAL~~VARNPLQGY~~YQVRRPS~~HEGYLA 1450
 APSLEGPGPDGDGQMQLVTSL 1471

Figure 2A

Figure 2B

4/11




Figure 3A

5/11




Figure 3B

[illegible]




Figure 4B

8/11




Figure 5




Figure 6




Figure 7A




Figure 7B